<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults - Oestreich, MC - 2020 | Cochrane Library</title> <meta content="Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults - Oestreich, MC - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013393.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults - Oestreich, MC - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013393.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013393.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults" name="citation_title"/> <meta content="Makinna C Oestreich" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Robin WM Vernooij" name="citation_author"/> <meta content="Niranjan J Sathianathen" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Eu Chang Hwang" name="citation_author"/> <meta content="Gretchen M Kuntz" name="citation_author"/> <meta content="University of Florida-Jacksonville" name="citation_author_institution"/> <meta content="Alex Koziarz" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Charles D Scales" name="citation_author"/> <meta content="Duke University School of Medicine" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="pdahm@umn.edu" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013393.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013393.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013393.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013393.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic alpha-1 Receptor Antagonists [*therapeutic use]; Chemotherapy, Adjuvant [methods]; Combined Modality Therapy [methods]; Doxazosin [therapeutic use]; Indoles [therapeutic use]; Kidney Calculi [*therapy]; *Lithotripsy; Prazosin [analogs &amp; derivatives, therapeutic use]; Quinazolines [therapeutic use]; Randomized Controlled Trials as Topic; Tamsulosin [therapeutic use]; Ureteral Calculi [*therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013393.pub2&amp;doi=10.1002/14651858.CD013393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013393\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013393\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013393.pub2",title:"Alpha\\u2010blockers after shock wave lithotripsy for renal or ureteral stones in adults",firstPublishedDate:"Nov 12, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013393.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013393.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013393.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013393.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013393.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013393.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013393.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013393.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013393.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013393.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4834 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013393.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-sec-0117"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/appendices#CD013393-sec-0122"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/table_n/CD013393StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/table_n/CD013393StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#CD013393-cr-0004">Makinna C Oestreich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#CD013393-cr-0005">Robin WM Vernooij</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#CD013393-cr-0006">Niranjan J Sathianathen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#CD013393-cr-0007">Eu Chang Hwang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#CD013393-cr-0008">Gretchen M Kuntz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#CD013393-cr-0009">Alex Koziarz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#CD013393-cr-0010">Charles D Scales</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information#CD013393-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Philipp Dahm</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information/en#CD013393-sec-0126">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013393.pub2">https://doi.org/10.1002/14651858.CD013393.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013393-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013393-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013393-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013393-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013393-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013393-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013393-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013393-abs-0001" lang="en"> <section id="CD013393-sec-0001"> <h3 class="title" id="CD013393-sec-0001">Background</h3> <p>Shock wave lithotripsy (SWL) is a widely used method to treat renal and ureteral stone. It fragments stones into smaller pieces that are then able to pass spontaneously down the ureter and into the bladder. Alpha‐blockers may assist in promoting the passage of stone fragments, but their effectiveness remains uncertain.  </p> </section> <section id="CD013393-sec-0002"> <h3 class="title" id="CD013393-sec-0002">Objectives</h3> <p>To assess the effects of alpha‐blockers as adjuvant medical expulsive therapy plus usual care compared to placebo and usual care or usual care alone in adults undergoing shock wave lithotripsy for renal or ureteral stones. </p> </section> <section id="CD013393-sec-0003"> <h3 class="title" id="CD013393-sec-0003">Search methods</h3> <p>We performed a comprehensive literature search of the Cochrane Library, the Cochrane Database of Systematic Reviews, MEDLINE, Embase, several clinical trial registries and grey literature for published and unpublished studies irrespective of language. The date of the most recent search was 27 February 2020. </p> </section> <section id="CD013393-sec-0004"> <h3 class="title" id="CD013393-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials of adults undergoing SWL. Participants in the intervention group had to have received an alpha‐blocker as adjuvant medical expulsive therapy plus usual care. For the comparator group, we considered studies in which participants received placebo. </p> </section> <section id="CD013393-sec-0005"> <h3 class="title" id="CD013393-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies for inclusion/exclusion, and performed data abstraction and risk of bias assessment. We conducted meta‐analysis for the identified dichotomous and continuous outcomes using RevManWeb according to Cochrane methods using a random‐effects model. We judged the certainty of evidence on a per outcome basis using GRADE. </p> </section> <section id="CD013393-sec-0006"> <h3 class="title" id="CD013393-sec-0006">Main results</h3> <p>We included 40 studies with 4793 participants randomized to usual care and an alpha‐blocker versus usual care alone. Only four studies were placebo controlled. The mean age of participants was 28.6 to 56.8 years and the mean stone size prior to SWL was 7.1 mm to 13.2 mm. The most widely used alpha‐blocker was tamsulosin; others were silodosin, doxazosin, terazosin and alfuzosin.  </p> <p>Alpha‐blockers may improve clearance of stone fragments after SWL (risk ratio (RR) 1.16, 95% confidence interval (CI) 1.09 to 1.23; I² = 78%; studies = 36; participants = 4084; low certainty evidence). Based on the stone clearance rate of 69.3% observed in the control arm, an alpha‐blocker may increase stone clearance to 80.4%. This corresponds to 111 more (62 more to 159 more) participants per 1000 clearing their stone fragments. </p> <p>Alpha‐blockers may reduce the need for auxiliary treatments after SWL (RR 0.67, 95% CI 0.45 to 1.00; I² = 16%; studies = 12; participants = 1251; low certainty evidence), but also includes the possibility of no effect. Based on a rate of auxiliary treatments in the usual care arm of 9.7%, alpha‐blockers may reduce the rate to 6.5%. This corresponds 32 fewer (53 fewer to 0 fewer) participants per 1000 undergoing auxiliary treatments. </p> <p>Alpha‐blockers may reduce major adverse events (RR 0.60, 95% CI 0.46 to 0.80; I² = 0%; studies = 7; participants = 747; low certainty evidence). Major adverse events occurred in 25.8% of participants in the usual care group; alpha‐blockers would reduce this to 15.5%. This corresponds to 103 fewer (139 fewer to 52 fewer) major adverse events per 1000 with alpha‐blocker treatment. None of the reported major adverse events appeared drug‐related; most were emergency room visits or rehospitalizations. </p> <p>Alpha‐blockers may reduce stone clearance time in days (mean difference (MD) –3.74, 95% CI –5.25 to –2.23; I² = 86%; studies = 14; participants = 1790; low certainty evidence). We found no evidence for the outcome of quality of life. </p> <p>For those outcomes for which we were able to perform subgroup analyses, we found no evidence of interaction with stone location, stone size or type of alpha‐blocker. We were unable to conduct an analysis by lithotripter type. The results were also largely unchanged when the analyses were limited to placebo controlled studies and those in which participants explicitly only received a single SWL session. </p> </section> <section id="CD013393-sec-0007"> <h3 class="title" id="CD013393-sec-0007">Authors' conclusions</h3> <p>Based on low certainty evidence, adjuvant alpha‐blocker therapy following SWL in addition to usual care may result in improved stone clearance, less need for auxiliary treatments, fewer major adverse events and a reduced stone clearance time compared to usual care alone. We did not find evidence for quality of life. The low certainty of evidence means that our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013393-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013393-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013393-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013393-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013393-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013393-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013393-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013393-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013393-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013393-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013393-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013393-abs-0002" lang="en"> <h3>After using shock waves to break up kidney stones, do medicines called alpha‑blockers help to get rid of the stone fragments? </h3> <p><b>What are kidney stones?</b> </p> <p>Waste products in the blood can sometimes form crystals that collect inside the kidneys. These can build up over time to form a hard stone‐like lump, called a kidney stone. </p> <p>Kidney stones can develop in both kidneys especially in people with certain medical conditions or who are taking certain medicines, or if people do not drink enough water or fluids. Stones can cause severe pain, fever and a kidney infection if they block the ureter. </p> <p><b>Treatments for kidney stones</b> </p> <p>Most stones are small enough to pass out in the urine: drinking plenty of water and other fluids will help. Larger kidney stones may be too big to pass out naturally and are usually removed by surgery. </p> <p>Shock wave lithotripsy is a non‐surgical way to treat stones in the kidney or ureter. High energy sound waves are applied to the outside of the body to break kidney stones into smaller pieces. After shock wave treatment, medicines called alpha‐blockers are sometimes given to help the stone fragments pass out naturally. </p> <p>Alpha‐blockers work by relaxing muscles and helping to keep blood vessels open. They are usually used to treat high blood pressure and problems with storing and passing urine in men who have an enlarged prostate gland. Alpha‐blockers may relax the muscle in the ureters, which might help to get rid of kidney stones and fragments.              </p> <p><b>Why we did this Cochrane Review</b> </p> <p>We wanted to find out how well alpha‐blockers work to help kidney stone fragments pass out in the urine. We also wanted to find out about potential unwanted effects that might be associated with alpha‐blockers. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at giving alpha‐blockers to adults, after shock wave treatment, to clear kidney stone fragments. </p> <p>We looked for randomized controlled studies, in which the treatments that people received were decided at random, because these studies usually give the most reliable evidence about the effects of a treatment. </p> <p><b>Search date:</b> we included evidence published up to 27 February 2020. </p> <p><b>What we found</b> </p> <p>We found 40 studies including 4793 people who had shock wave treatment to break up their kidney stones. Most of the studies were done in Asia; some were in Europe, Africa and South America. Most studies did not report their sources of funding. </p> <p>The studies compared giving an alpha‐blocker with giving a placebo (dummy) treatment or usual care (could include antibiotics, painkillers and fluids given by mouth or through a drip). </p> <p>Tamsulosin was the most commonly studied alpha‐blocker; the others were silodosin, doxazosin, terazosin and alfuzosin. </p> <p><b>What are the results of our review?</b> </p> <p>Compared with usual care or a placebo treatment, alpha‐blockers may:</p> <p>clear kidney stones in more people: in 111 more people for every 1000 people treated (36 studies); </p> <p>clear stones faster: by nearly four days (14 studies);</p> <p>reduce the need for extra treatments to clear stones: in 32 fewer people for every 1000 people treated (12 studies); and </p> <p>cause fewer unwanted effects: affecting 103 fewer people for every 1000 people treated (seven studies). </p> <p>Most unwanted effects were emergency visits to hospitals, and people going back into hospital for stone related problems. Unwanted effects were more common in people who had usual care or a placebo treatment than in people given alpha‐blockers. </p> <p>None of the studies looked at people's quality of life (well‐being).</p> <p><b>How reliable are these results?</b> </p> <p>We are uncertain about these results because they were based on studies in which it was unclear how people were chosen to take part; it was unclear if results were reported fully; some results were inconsistent and in some studies the results varied widely.  Our results are likely to change if further evidence becomes available. </p> <p><b>Conclusions</b> </p> <p>Giving an alpha‐blocker after shock wave treatment to break up kidney stones might clear the fragments faster, in more people and reduce the need for extra treatments. Alpha‑blockers might cause fewer unwanted effects than usual care or a placebo. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013393-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013393-sec-0117"></div> <h3 class="title" id="CD013393-sec-0118">Implications for practice</h3> <section id="CD013393-sec-0118"> <p>Findings of this review indicate that there may be a benefit of medical expulsive therapy across the three predefined outcomes considered the most important: namely, stone clearance, auxiliary treatment and major adverse events. The certainty of evidence was consistently low. This means that our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. We did not eligible information on quality of life. </p> </section> <h3 class="title" id="CD013393-sec-0119">Implications for research</h3> <section id="CD013393-sec-0119"> <p>The low certainty of evidence resulting from trials of low methodological rigor with poor reporting quality of small sample size and without stratification for important prognostic variables such as stone size and location implies a need for better trials as have been conducted for the use of alpha‐blockers for ureteral colic (<a href="./references#CD013393-bbs2-0121" title="PickardR , StarrK , MacLennanG , LamT , ThomasR , BurrJ , et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet2015;386(9991):341-9.">Pickard 2015</a>; <a href="./references#CD013393-bbs2-0149" title="YeZ , ZengG , YangH , TangK , ZhangX , LiH , et al. Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: a multicenter, randomized, double-blind, placebo-controlled trial. European Urology2018;73(3):385-91.">Ye 2018</a>). Future trials need to meet higher methodological standards which includes an a priori registered protocol (<a href="./references#CD013393-bbs2-0125" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463.">Roberts 2015</a>). In addition, quality of life outcomes should be assessed.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013393-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013393-sec-0008"></div> <div class="table" id="CD013393-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Alpha‐blocker as adjuvant medical expulsive therapy plus usual care compared to usual care for renal and ureteral stones</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Alpha‐blocker and usual care compared to usual care for renal and ureteral stones</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with renal and ureteral stones undergoing shock wave lithotripsy<br/><b>Setting:</b> outpatient or inpatient<br/><b>Intervention:</b> alpha‐blocker and usual care<br/><b>Comparison:</b> usual care </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Effect size<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard care</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with alpha‐blocker</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stone clearance</b> </p> <p>assessed by imaging</p> <p>Follow‐up range: 1 week to 3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4084<br/>(36 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b><br/>(1.09 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Moderate risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>693 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 more per 1000<br/>(62 more to 159 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Auxiliary treatment</b> </p> <p>Follow‐up range: 1 week to 3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1251<br/>(12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.67</b> </p> <p>(0.45 to 1.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Moderate risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 fewer per 1000</p> <p>(53 fewer to 0 fewer)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Major adverse events</b> </p> <p>determined by study investigators</p> <p>Follow‐up range: 1 week to 3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>747<br/>(7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.60</b><br/>(0.46 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Moderate risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 fewer per 1000<br/>(139 fewer to 52 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b><sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 fewer per 1000</p> <p>(139 fewer to 34 fewer)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stone clearance time</b> </p> <p>measured in days </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1790<br/>(14 studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,g,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Moderate risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 3.61–47.2 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.74 fewer days</p> <p>(5.25 fewer to 2.23 fewer days)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>N/A:</b> not applicable; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for unclear risk of selection bias, high risk of performance and detection bias, and unclear risk of selective reporting bias.<br/><sup>b</sup>Downgraded one level due to clinically important, unexplained inconsistency with high I² value.<br/><sup>c</sup>Concerns over possible publication bias given funnel plot asymmetry contributed to decision to downgraded by two levels overall.<br/><sup>d</sup>Imprecision with wide confidence intervals around absolute effect size estimates that crossed the threshold of 3% clinically relevant absolute risk reduction.<br/><sup>e</sup>Downgraded two levels for unclear risk of selection bias, high risk of performance and detection bias, and high risk of selective reporting bias for this infrequently reported outcome.<br/><sup>f</sup>Lower, presumably more representative control event rate of 17% obtained by excluding <a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>.<br/><sup>g</sup>Downgraded one level given funnel plot asymmetry and serious risk of publication bias.<br/><sup>h</sup>We noted a high degree of inconsistency but did not downgrade given its perceived lack of clinical importance. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013393-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013393-sec-0009"></div> <section id="CD013393-sec-0010"> <h3 class="title" id="CD013393-sec-0010">Description of the condition</h3> <p>Urinary tract stones are the result of a complex cascade of events that involves supersaturation of stone forming salts that precipitate out of solution to form crystals or nuclei. Once formed, these can either flow out and be excreted or they are retained in the kidney where crystals can aggregate and grow to form macroscopic stones that may cause urinary symptoms and obstruction. </p> <p>Urinary tract stones are a common urologic problem and the worldwide prevalence and incidence is increasing (<a href="./references#CD013393-bbs2-0075" title="ChewcharatA , CurhanG . Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis2020;N/A:N/A.">Chewcharat 2020</a>; <a href="./references#CD013393-bbs2-0126" title="RomeroV , AkpinarH , AssimosDG . Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Reviews in Urology2010;12(2-3):e86-96. [PMID: 20811557]">Romero 2010</a>). The prevalence has been reported as 16.9% in 1997 in Thailand, 14.8% in 1989 in Turkey and 14% in 2013/2014 in England (<a href="./references#CD013393-bbs2-0126" title="RomeroV , AkpinarH , AssimosDG . Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Reviews in Urology2010;12(2-3):e86-96. [PMID: 20811557]">Romero 2010</a>; <a href="./references#CD013393-bbs2-0128" title="RukinNJ , SiddiquiZA , ChedgyEC , SomaniBK . Trends in upper tract stone disease in England: evidence from the Hospital Episodes Statistics database. Urologia Internationalis2017;98(4):391-6. [PMID: 27694759]">Rukin 2017</a>). In the USA, the prevalence of stone disease has been estimated at 10.6% in men and 7.1% in women in the 2007–2010 National Health and Nutrition Examination Survey (<a href="./references#CD013393-bbs2-0133" title="Scales CD Jr, SmithAC , HanleyJM , SaigalCS . Prevalence of kidney stones in the United States. European Urology2012;62(1):160-5. [PMID: 22498635]">Scales 2012</a>). Proposed modifiable risk factors include maintaining a normal body mass index, drinking an adequate fluids, and eating fruits and vegetables (<a href="./references#CD013393-bbs2-0085" title="FerraroPM , TaylorEN , GambaroG , CurhanGC . Dietary and lifestyle risk factors associated with incident kidney stones in men and women. Journal of Urology2017;198(4):858-63.">Ferraro 2017</a>). The cost of this disease is high, with estimates upwards of several billion dollars in 2000 in the USA (<a href="./references#CD013393-bbs2-0129" title="SaigalCS , JoyceG , TimilsinaAR . Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management?Kidney International2005;68(4):1808-14. [PMID: 16164658]">Saigal 2005</a>). There are variable costs associated with urinary tract stones based on acute, medical or surgical management options (<a href="./references#CD013393-bbs2-0074" title="CanvasserNE , AlkenP , LipkinM , NakadaSY , SodhaHS , TepelerA , et al. The economics of stone disease. World Journal of Urology2017;35(9):1321-9. [PMID: 28108799]">Canvasser 2017</a>). </p> <section id="CD013393-sec-0011"> <h4 class="title">Diagnosis</h4> <p>People presenting with clinical suspicion for symptomatic urinary tract stones are evaluated with history and physical exam, followed by imaging studies. The primary imaging modality used depends on the availability of the tools. In an older study of people presenting to an emergency room with a stone, 90% had acute unilateral flank pain, hematuria, and positive imaging by kidney, ureter and bladder (KUB) radiograph (<a href="./references#CD013393-bbs2-0082" title="EltonTJ , RothCS , BerquistTH , SilversteinMD . A clinical prediction rule for the diagnosis of ureteral calculi in emergency departments. Journal of General Internal Medicine1993;8(2):57-62. [PMID: 8441076]">Elton 1993</a>). The European Association of Urology (EAU) now recommends ultrasound as the initial diagnostic imaging tool in people suspected of urinary tract stones due to its safety profile and low cost (<a href="./references#CD013393-bbs2-0143" title="TurkC , PetrikA , SaricaK , SeitzC , SkolarikosA , StraubM , et al. EAU guidelines on diagnosis and conservative management of urolithiasis. European Urology2016;69(3):468-74. [PMID: 26318710]">Turk 2016</a>). However, imaging beyond ultrasound may be needed to best characterize the stone and its location. Non‐contrast‐enhanced computed tomography (NCCT) is the gold standard diagnostic tool for nephrolithiasis in any location of the urinary tract. It characterizes stone density and determines precise location including defining skin‐to‐stone distance – factors important in determining the best treatment modality (<a href="./references#CD013393-bbs2-0081" title="El-NahasAR , El-AssmyAM , MansourO , SheirKZ . A prospective multivariate analysis of factors predicting stone disintegration by extracorporeal shock wave lithotripsy: the value of high-resolution noncontrast computed tomography. European Urology2007;51(6):1688-93; discussion 1693-4. [PMID: 17161522]">El‐Nahas 2007</a>; <a href="./references#CD013393-bbs2-0105" title="KimSC , BurnsEK , LingemanJE , PatersonRF , McAteerJA , Williams JC Jr. Cystine calculi: correlation of CT-visible structure, CT number, and stone morphology with fragmentation by shock wave lithotripsy. Urological Research2007;35(6):319-24. [PMID: 17965956]">Kim 2007</a>; <a href="./references#CD013393-bbs2-0150" title="ZarseCA , HameedTA , JacksonME , PishchalnikovYA , LingemanJE , McAteerJA , et al. CT visible internal stone structure, but not Hounsfield unit value, of calcium oxalate monohydrate (COM) calculi predicts lithotripsy fragility in vitro. Urological Research2007;35(4):201-6. [PMID: 17565491]">Zarse 2007</a>). NCCT has largely replaced intravenous urography in diagnosing acute urinary tract stones due to its higher diagnostic accuracy (<a href="./references#CD013393-bbs2-0147" title="WorsterA , PreyraI , WeaverB , HainesT . The accuracy of noncontrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis: a meta-analysis. Annals of Emergency Medicine2002;40(3):280-6. [PMID: 12192351]">Worster 2002</a>). It also represents the most accurate treatment modality to establish treatment success but has the downside of costs and radiation exposure. </p> </section> <section id="CD013393-sec-0012"> <h4 class="title">Treatment</h4> <p>Urinary tract stones may pass on their own or require intervention to assist with expulsion. The likelihood of spontaneous passage depends on the size and location of the stone. Smaller stones located more distally in the urinary tract, notably the distal ureter and beyond, have the highest rates of spontaneous passage (<a href="./references#CD013393-bbs2-0099" title="HubnerWA , IrbyP , StollerML . Natural history and current concepts for the treatment of small ureteral calculi. European Urology1993;24(2):172-6. [PMID: 8375436]">Hubner 1993</a>). Segments of the ureter are defined radiographically: proximal from its origin to the upper border of the sacroiliac joint; middle overlying the SI joint; and distal from the lower border of the sacroiliac joint and beyond. Ureteral stones less than 10 mm have the highest incidence of spontaneous expulsion, and the American Urological Association (AUA) recommends observation with trial of passage in people whose pain is well controlled and are free of signs of infection or high grade obstruction (<a href="./references#CD013393-bbs2-0069" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part I. Journal of Urology2016;196(4):1153-60. [PMID: 27238616]">Assimos 2016a</a>; <a href="./references#CD013393-bbs2-0070" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part II. Journal of Urology2016;196(4):1161-9. [PMID: 27238615]">Assimos 2016b</a>). Furthermore, for uncomplicated ureteral colic due to ureteral stones of the distal ureter, these guidelines recommend medical expulsive therapy (MET) with alpha‐blockers (alpha‐adrenoreceptor antagonists) (<a href="./references#CD013393-bbs2-0069" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part I. Journal of Urology2016;196(4):1153-60. [PMID: 27238616]">Assimos 2016a</a>; <a href="./references#CD013393-bbs2-0070" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part II. Journal of Urology2016;196(4):1161-9. [PMID: 27238615]">Assimos 2016b</a>). A panel using GRADE and following the <i>British Medical Journal</i> (BMJ) Rapid Recommendations procedure recommend MET, even in settings when stone size and location has not been established by imaging studies (<a href="./references#CD013393-bbs2-0145" title="VermandereM , KuijpersT , BurgersJS , KunnamoI , vanLieshoutJ , WallaceE , et al. alpha-Blockers for uncomplicated ureteric stones: a clinical practice guideline. BJU International2018;122(6):924-31.">Vermandere 2018</a>). Supporting evidence for the use of MET as primary treatment for ureteral stones comes from several high‐quality reviews (<a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a>; <a href="./references#CD013393-bbs2-0098" title="HollingsworthJM , CanalesBK , RogersMA , SukumarS , YanP , KuntzGM , et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ (Clinical Research Ed.)2016;355:i6112. [PMID: 27908918]">Hollingsworth 2016</a>). It should be noted that MET is an off‐label indication for alpha‐blockers and their actual value for this indication remains controversial given concerns over the quality of the underlying trials as well as their adverse effects and costs (<a href="./references#CD013393-bbs2-0079" title="De ConinckV , AntonelliJ , ChewB , PattersonJM , SkolarikosA , BultitudeM . Medical expulsive therapy for urinary stones: future trends and knowledge gaps. European Urology2019;76(5):658-66.">De Coninck 2019</a>; <a href="./references#CD013393-bbs2-0121" title="PickardR , StarrK , MacLennanG , LamT , ThomasR , BurrJ , et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet2015;386(9991):341-9.">Pickard 2015</a>). In addition,  people with a more complicated presentation, for example those with signs of a systemic infection, as witnessed by fever or an elevated white blood cell count (or both), should undergo immediate urinary drainage by ureteral stent or percutaneous nephrostomy placement. </p> <p>Renal colic is a likely symptom of acute stone episodes and must be treated accordingly. Pain management is part of the usual treatment regimen for symptomatic stones. The EAU and AUA recommend non‐steroidal anti‐inflammatory drugs (NSAIDs) including metamizole to treat renal colic (<a href="./references#CD013393-bbs2-0069" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part I. Journal of Urology2016;196(4):1153-60. [PMID: 27238616]">Assimos 2016a</a>; <a href="./references#CD013393-bbs2-0070" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part II. Journal of Urology2016;196(4):1161-9. [PMID: 27238615]">Assimos 2016b</a>; <a href="./references#CD013393-bbs2-0143" title="TurkC , PetrikA , SaricaK , SeitzC , SkolarikosA , StraubM , et al. EAU guidelines on diagnosis and conservative management of urolithiasis. European Urology2016;69(3):468-74. [PMID: 26318710]">Turk 2016</a>). Definitive stone treatment may be offered to patients if spontaneous stone passage is not achieved or sooner intervention is clinically necessary. The typical timeframe for a trial of spontaneous passage ranges from four to six weeks. People with pain uncontrolled with oral analgesics, worsening renal function or sepsis from the urinary tract require surgical management, either definitive management with stone removal or urinary drainage (in the setting of signs of sepsis) (<a href="./references#CD013393-bbs2-0069" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part I. Journal of Urology2016;196(4):1153-60. [PMID: 27238616]">Assimos 2016a</a>; <a href="./references#CD013393-bbs2-0070" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part II. Journal of Urology2016;196(4):1161-9. [PMID: 27238615]">Assimos 2016b</a>; <a href="./references#CD013393-bbs2-0143" title="TurkC , PetrikA , SaricaK , SeitzC , SkolarikosA , StraubM , et al. EAU guidelines on diagnosis and conservative management of urolithiasis. European Urology2016;69(3):468-74. [PMID: 26318710]">Turk 2016</a>). Two commonly used options for definitive management are ureteroscopy (URS) and shock wave lithotripsy (SWL). An advantage of URS is the greater stone free rate, which has been shown even when stones less than 10 mm are stratified by location in the ureter (<a href="./references#CD013393-bbs2-0123" title="PremingerGM , TiseliusHG , AssimosDG , AlkenP , BuckC , GallucciM , et al. 2007 Guideline for the management of ureteral calculi. Journal of Urology2007;178(6):2418-34. [PMID: 17993340]">Preminger 2007</a>). The higher stone free rate after a single procedure is particularly notable for distal ureteral stones, and thus URS typically is recommended over SWL. Advantages of SWL over URS are decreased complication rates and lower morbidity (<a href="./references#CD013393-bbs2-0067" title="AboumarzoukOM , KataSG , KeeleyFX , McClintonS , NabiG . Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006029. [DOI: 10.1002/14651858.CD006029.pub4]">Aboumarzouk 2012</a>). The complications of urinary tract infections (UTI), ureteral strictures and ureteral avulsion are similar between SWL and URS, but URS has a higher risk of ureteral perforation (<a href="./references#CD013393-bbs2-0067" title="AboumarzoukOM , KataSG , KeeleyFX , McClintonS , NabiG . Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006029. [DOI: 10.1002/14651858.CD006029.pub4]">Aboumarzouk 2012</a>). Additional options for definitive treatment of stones include percutaneous nephrolithotomy (PCNL), laparoscopic, open surgical removal or robotic surgical removal. </p> <p>SWL is a non‐invasive procedure where high energy shock waves are applied to the outside of the body to break up urinary tract stones in the kidney and ureter. The tiny stone fragments can then pass through the urinary system to be excreted. To aid in patient comfort, SWL may be performed under mild sedation, or local or general anesthesia. Fluoroscopy or ultrasound (or both) are used for imaging studies throughout the procedure to localize the stones and monitor treatment progression (<a href="./references#CD013393-bbs2-0107" title="KohrmannKU , RassweilerJJ , ManningM , MohrG , HenkelTO , JunemannKP , et al. The clinical introduction of a third generation lithotriptor: Modulith SL 20. Journal of Urology1995;153(5):1379-83.">Kohrmann 1995</a>). The technique of SWL encompasses several factors to optimize treatment outcomes (<a href="./references#CD013393-bbs2-0114" title="MatlagaBR , KrambeckAE , LingemanJE . Surgical management of upper urinary tract calculi. In: WeinAJ , KavoussiLR , PartinAE , PetersCA , editors(s). Campbell-Walsh Urology. 11th edition. Vol. 54. Philadelphia (PA): Elsevier, 2016:1260-90.e7.">Matlaga 2016</a>). Modifiable SWL parameters include the number of shocks, period of shock wave administration, voltage, type of shock wave generator and rate of shock wave delivery. A large skin‐to‐stone distance negatively impact stone fragmentation (<a href="./references#CD013393-bbs2-0119" title="PareekG , HedicanSP , Lee FT Jr, NakadaSY . Shock wave lithotripsy success determined by skin-to-stone distance on computed tomography. Urology2005;66(5):941-4.">Pareek 2005</a>). In addition, focal zones differ considerably by lithotripter type, manufacturer and model, and can greatly impact stone fragmentation effectiveness. Of note, current evidence based guidelines only recommend SWL in people with normal anatomy of the collecting system, normal renal function and the absence of infection. Given its unknown effect on the fetus (especially given the common use of fluoroscopy), SWL is contraindicated in pregnant women (<a href="./references#CD013393-bbs2-0069" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part I. Journal of Urology2016;196(4):1153-60. [PMID: 27238616]">Assimos 2016a</a>; <a href="./references#CD013393-bbs2-0070" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part II. Journal of Urology2016;196(4):1161-9. [PMID: 27238615]">Assimos 2016b</a>; <a href="./references#CD013393-bbs2-0143" title="TurkC , PetrikA , SaricaK , SeitzC , SkolarikosA , StraubM , et al. EAU guidelines on diagnosis and conservative management of urolithiasis. European Urology2016;69(3):468-74. [PMID: 26318710]">Turk 2016</a>; <a href="./references#CD013393-bbs2-0144" title="TurkC , NeisiusA , PetrikA , SeitzC , SkolarikosA . EAU urolithiasis guidelines, 2020. uroweb.org/guideline/urolithiasis (accessed prior to 19 August 2020).">Turk 2020</a>). </p> <p>Further possible complications from SWL of renal or ureteral stones are related to incomplete stone fragmentation and renal colic symptoms when fragments cause distention and obstruction of the ureter (<a href="./references#CD013393-bbs2-0140" title="SkolarikosA , AlivizatosG , deLa RosetteJ . Extracorporeal shock wave lithotripsy 25 years later: complications and their prevention. European Urology2006;50(5):990-81.">Skolarikos 2006</a>). The term steinstrasse refers to when multiple stone fragments or debris line the ureter (<a href="./references#CD013393-bbs2-0132" title="SayedMA , el-TaherAM , Aboul-EllaHA , ShakerSE . Steinstrasse after extracorporeal shockwave lithotripsy: aetiology, prevention and management. BJU International2001;88(7):675-8. [PMID: 11890235]">Sayed 2001</a>). Steinstrasse occurs in 1% to 4% of SWL cases (<a href="./references#CD013393-bbs2-0113" title="MadboulyK , SheirKZ , ElsobkyE , ErakyI , KenawyM . Risk factors for the formation of a steinstrasse after extracorporeal shock wave lithotripsy: a statistical model. Journal of Urology2002;167(3):1239-42. [PMID: 11832705]">Madbouly 2002</a>). This complication can lead to clinically significant obstruction, pain and infection (<a href="./references#CD013393-bbs2-0132" title="SayedMA , el-TaherAM , Aboul-EllaHA , ShakerSE . Steinstrasse after extracorporeal shockwave lithotripsy: aetiology, prevention and management. BJU International2001;88(7):675-8. [PMID: 11890235]">Sayed 2001</a>). Trauma to the kidneys causes bleeding in the urinary tract when SWL is performed. The shock waves cause small vessels in the kidney to rupture which can lead to hematoma formation (<a href="./references#CD013393-bbs2-0114" title="MatlagaBR , KrambeckAE , LingemanJE . Surgical management of upper urinary tract calculi. In: WeinAJ , KavoussiLR , PartinAE , PetersCA , editors(s). Campbell-Walsh Urology. 11th edition. Vol. 54. Philadelphia (PA): Elsevier, 2016:1260-90.e7.">Matlaga 2016</a>). </p> </section> </section> <section id="CD013393-sec-0013"> <h3 class="title" id="CD013393-sec-0013">Description of the intervention</h3> <p>Alpha‐blockers work by relaxing smooth muscle and help keep small blood vessels open. Examples of alpha‐blockers include tamsulosin, alfuzosin, terazosin, naftopidil and silodosin. They are typically used to treat or improve symptoms of high blood pressure and benign prostatic hyperplasia (BPH), and are particularly helpful if a person has both conditions. Because there is a lack of evidence supporting the cardioprotective effects of alpha‐blockers compared to placebo, alpha‐blockers are no longer recommended as first‐line treatment for high blood pressure (<a href="./references#CD013393-bbs2-0122" title="Pool, JL. α-Adrenoceptor blockers for management of hypertension in the elderly. In: PrisantLM , editors(s). Hypertension in the Elderly (Clinical Hypertension and Vascular Diseases). Totowa (NJ): Humana Press, 2005.">Pool 2005</a>). Alpha‐blockers have been shown to improve lower urinary tract symptoms (LUTS), the complex of symptoms associated with BPH (<a href="./references#CD013393-bbs2-0137" title="ShapiroE , HartantoV , LeporH . The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate1992;21(4):297-307.">Shapiro 1992</a>). The rationale for the use of alpha‐blockers is that LUTS are at least partly due to bladder outlet obstruction, a process mediated by alpha<sub>1</sub> adrenoreceptors in prostatic smooth muscle (<a href="./references#CD013393-bbs2-0072" title="CaineM , PfauA , PerlbergS . The use of alpha-adrenergic blockers in benign prostatic obstruction. British Journal of Urology1976;48(4):255-63. [PMID: 61054]">Caine 1976</a>). </p> <p>Alpha‐blockers are available as an adjuvant medical therapy to enhance stone fragment passage after SWL. If fragments do not readily pass after SWL, patients can develop complications including steinstrasse. Urinary tract obstruction, infection and significant pain can develop from incomplete stone passage. The use of SWL as treatment for stones may result in need for repeat or additional procedures to clear all stone fragments. Therefore, we are interested in the use of alpha‐blockers to facilitate stone passage after SWL. Like MET for improvement of spontaneous stone passage, MET after SWL is an off‐label use of the medication in the USA (<a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a>). </p> <section id="CD013393-sec-0014"> <h4 class="title">Adverse effects of the intervention</h4> <p>The most frequent adverse effects of alpha‐blockers are related to the cardiovascular system. The <a href="./references#CD013393-bbs2-0068" title="American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society2015;63(11):2227-46.">American Geriatrics Society 2015</a> recommends avoidance of the alpha‐blockers doxazosin, prazosin and terazosin as antihypertensive medications in elderly people due to the high risk of orthostatic hypotension. Because of the risk of orthostatic hypotension, as well as bradycardia, avoidance of use in people with history of syncope is also recommended (<a href="./references#CD013393-bbs2-0071" title="Boehringer Ingelheim Pharmaceuticals, Incorporated. Product Information: Flomax(R) oral capsules, tamsulosin HCl oral capsules. www.accessdata.fda.gov/drugsatfda_docs/label/2005/020579s016lbl.pdf (accessed prior to 26 June 2019).">Boehringer 2019</a>). Alpha‐blockers may exacerbate heart failure. Tamsulosin has been reported to cause atrial fibrillation in postmarketing studies (<a href="./references#CD013393-bbs2-0071" title="Boehringer Ingelheim Pharmaceuticals, Incorporated. Product Information: Flomax(R) oral capsules, tamsulosin HCl oral capsules. www.accessdata.fda.gov/drugsatfda_docs/label/2005/020579s016lbl.pdf (accessed prior to 26 June 2019).">Boehringer 2019</a>). Additionally, those studies have reported adverse effects of palpitations, peripheral edema, tachycardia and cardiac dysrhythmia. </p> <p>Adverse effects of terazosin on the genitourinary tract have been reported. Erectile dysfunction has been known to occur in 1.2% to 1.6% of men (<a href="./references#CD013393-bbs2-0066" title="Abbott Laboratories. Product information: HYTRIN(R) oral tablets, terazosin HCl oral tablets. www.accessdata.fda.gov/drugsatfda_docs/label/2009/019057s022lbl.pdf (accessed prior to 26 June 2019).">Abbott Laboratories 2019</a>). Priapism – prolonged and painful erection of the penis – has been reported, but only rarely (<a href="./references#CD013393-bbs2-0066" title="Abbott Laboratories. Product information: HYTRIN(R) oral tablets, terazosin HCl oral tablets. www.accessdata.fda.gov/drugsatfda_docs/label/2009/019057s022lbl.pdf (accessed prior to 26 June 2019).">Abbott Laboratories 2019</a>). Abnormal ejaculation has been reported with alpha‐blocker use. In men taking tamsulosin, the incidence of abnormal ejaculation is between 8.4% and 18.1% (<a href="./references#CD013393-bbs2-0071" title="Boehringer Ingelheim Pharmaceuticals, Incorporated. Product Information: Flomax(R) oral capsules, tamsulosin HCl oral capsules. www.accessdata.fda.gov/drugsatfda_docs/label/2005/020579s016lbl.pdf (accessed prior to 26 June 2019).">Boehringer 2019</a>). The abnormal ejaculation was reversible in 76% of men upon discontinuation of the drug (<a href="./references#CD013393-bbs2-0097" title="HofnerK , ClaesH , De ReijkeTM , FolkestadB , SpeakmanMJ . Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology1999;36(4):335-41. [PMID: 10473995]">Hofner 1999</a>). Decreased ejaculate volume has been reported in 89.6% of men taking tamsulosin, and anejaculation, the lack of any ejaculation, has been reported in 35.4% of men taking tamsulosin (<a href="./references#CD013393-bbs2-0090" title="HellstromWJ , SikkaSC . Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. Journal of Urology2006;176(4 Pt 1):1529-33. [PMID: 16952675]">Hellstrom 2006</a>). Furthermore, alpha‐blockers may worsen incontinence in women with stress or mixed urinary incontinence (<a href="./references#CD013393-bbs2-0106" title="KirulutaGH , MercerAR , WinsorGM . Prazosin as cause of urinary incontinence. Urology1981;18(6):618-9. [PMID: 6118972]">Kiruluta 1981</a>; <a href="./references#CD013393-bbs2-0142" title="ThienT , DelaereKP , DebruyneFM , KoeneRA . Urinary incontinence caused by prazosin. British Medical Journal1978;1(6113):622-3. [PMID: 564728]">Thien 1978</a>). </p> </section> </section> <section id="CD013393-sec-0015"> <h3 class="title" id="CD013393-sec-0015">How the intervention might work</h3> <p>The rationale for the use of alpha‐blockers as an adjuvant medical therapy for stones is based on the natural history of stones causing contraction of the ureters during passage that may inhibit expulsion. Contractility of the ureters is mediated by alpha‐ and beta‐adrenoreceptors located in the ureteral walls (<a href="./references#CD013393-bbs2-0120" title="ParkHK , ChoiEY , JeongBC , KimHH , KimBK . Localizations and expressions of α-1A, α-1B and α-1D adrenoceptors in human ureter. Urological Research2007;35(6):325-9.">Park 2007</a>). The ureters contains alpha<sub>1D</sub>‐ and alpha<sub>1A</sub>‐adrenoreceptor subtypes and the less prevalent alpha<sub>1B</sub>‐adrenoreceptor subtype (<a href="./references#CD013393-bbs2-0101" title="ItohY , KojimaY , YasuiT , TozawaK , SasakiS , KohriK . Examination of alpha 1 adrenoceptor subtypes in the human ureter. International Journal of Urology2007;14(8):749-53.">Itoh 2007</a>; <a href="./references#CD013393-bbs2-0104" title="KarabacakOR , YilmazerD , OzturkU , SenerNC , SaltasH , KarabacakY , et al. The presence and distribution of alpha adrenergic receptors in human renal pelvis and calyces. Urolithiasis2013;41(5):385-8. [PMID: 23877383]">Karabacak 2013</a>; <a href="./references#CD013393-bbs2-0138" title="SigalaS , DellabellaM , MilaneseG , FornariS , FaccoliS , PalazzoloF , et al. Evidence for the presence of α1 adrenoceptor subtypes in the human ureter. Neurourology and Urodynamics2005;24(2):142-8.">Sigala 2005</a>). The distal ureter contains the highest density of alpha<sub>1</sub>‐adrenoreceptors, as observed based on the ability of the distal ureter to generate a higher contractile force compared to the proximal ureter (<a href="./references#CD013393-bbs2-0131" title="SasakiS , TomiyamaY , KobayashiS , KojimaY , KubotaY , KohriK . Characterization of alpha1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology2011;77(3):762.e13-7. [PMID: 21195469]">Sasaki 2011</a>). </p> <p>Adrenergic transmission is mediated by the chemical norepinephrine, which is synthesized within neurons. Norepinephrine activates alpha‐adrenoreceptors and causes stimulation of ureteral activity (<a href="./references#CD013393-bbs2-0091" title="HernándezM , PrietoD , SimonsenU , RiveraL , BarahonaMV , García-SacristánA . Noradrenaline modulates smooth muscle activity of the isolated intravesical ureter of the pig through different types of adrenoceptors. British Journal of Pharmacology1992;107(4):924-31.">Hernández 1992</a>; <a href="./references#CD013393-bbs2-0116" title="McLeodDG , ReynoldsDG , SwanKG . Adrenergic mechanisms in the canine ureter. American Journal of Physiology ‒ Legacy Content1973;224(5):1054-8.">McLeod 1973</a>). Stimulation of alpha‐adrenoreceptors has been shown to increase contraction of ureteral smooth muscle and promote more frequent peristalsis (<a href="./references#CD013393-bbs2-0120" title="ParkHK , ChoiEY , JeongBC , KimHH , KimBK . Localizations and expressions of α-1A, α-1B and α-1D adrenoceptors in human ureter. Urological Research2007;35(6):325-9.">Park 2007</a>; <a href="./references#CD013393-bbs2-0131" title="SasakiS , TomiyamaY , KobayashiS , KojimaY , KubotaY , KohriK . Characterization of alpha1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology2011;77(3):762.e13-7. [PMID: 21195469]">Sasaki 2011</a>). Therefore, blockade of alpha‐adrenoreceptors with alpha‐blockers leads to decrease in ureteral contractions (<a href="./references#CD013393-bbs2-0127" title="RoseJG , GillenwaterJY . The effect of adrenergic and cholinergic agents and their blockers upon ureteral activity. Investigative Urology1974;11(6):439-51. [PMID: 4151303]">Rose 1974</a>). The decrease in ureteral spasm by alpha‐blockers has the potential benefit of easing spontaneous passage of stones by increasing the rate of expulsion and decreasing pain (<a href="./references#CD013393-bbs2-0077" title="CrowleyAR , ByrneJC , Vaughan ED Jr, MarionDN . The effect of acute obstruction on ureteral function. Journal of Urology1990;143(3):596-9. [PMID: 2304180]">Crowley 1990</a>; <a href="./references#CD013393-bbs2-0108" title="LairdJM , RozaC , CerveroF . Effects of artificial calculosis on rat ureter motility: peripheral contribution to the pain of ureteric colic. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology1997;272(5):R1409-16.">Laird 1997</a>). It is the alpha‐blockers that have selectivity for alpha<sub>1A</sub>‐adrenoreceptor subtype, namely alfuzosin, doxazosin, prazosin, tamsulosin, terazosin and silodosin, that have primarily been used for MET. </p> <p>Pharmacological agents that facilitate ureteral relaxation have the potential to aid in stone expulsion (<a href="./references#CD013393-bbs2-0139" title="SivulaA , LehtonenT . Spontaneous passage of artificial concretions applied in the rabbit ureter. Scandinavian Journal of Urology and Nephrology1967;1(3):259-63.">Sivula 1967</a>). Medications with alpha‐blocking activity help to relax ureteral smooth muscle and could aid in stone passage. Other agents that mediate ureteral relaxation through mechanisms other than alpha‐adrenoreceptors (for example, calcium channel blockers) have been explored in enhancing stone passage, but are outside the scope of this review (<a href="./references#CD013393-bbs2-0087" title="GuptaA , AboumarzoukOM , JefferiesMT , KynastonHG , DattaS . Calcium channel blockers as medical expulsive therapy for ureteric stones. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD011162. [DOI: 10.1002/14651858.CD011162]">Gupta 2014</a>; <a href="./references#CD013393-bbs2-0121" title="PickardR , StarrK , MacLennanG , LamT , ThomasR , BurrJ , et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet2015;386(9991):341-9.">Pickard 2015</a>). </p> </section> <section id="CD013393-sec-0016"> <h3 class="title" id="CD013393-sec-0016">Why it is important to do this review</h3> <p>Whereas several trials have been conducted to assess the effect of alpha‐blockers in people undergoing SWL for urinary tract stones, there is no consensus as to its effects. Underlying issues relate to clinical differences between trials, such as the type of lithotripter and the definition used for successful stone fragmentation as well as varying methodological quality of these trials. These issues mirror those in the use of alpha‐blockers in people with ureteral colic which were addressed in one Cochrane Review (<a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a>). <a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a> and another high‐quality review (<a href="./references#CD013393-bbs2-0098" title="HollingsworthJM , CanalesBK , RogersMA , SukumarS , YanP , KuntzGM , et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ (Clinical Research Ed.)2016;355:i6112. [PMID: 27908918]">Hollingsworth 2016</a>) have suggested a possible subgroup effect based on stone size with greater effectiveness in larger stones (5 mm and greater). This appear relevant to our review given that SWL stone fragments can be expected to be smaller (3 mm or less) in size, thereby drawing into question the effectiveness of MET in this setting. Our review will, therefore, address the specific clinical scenario of alpha‐blocker use after SWL. Adjuvant treatment to SWL may provide important benefits for people with residual fragments after SWL. There is potential to accelerate stone passage, thereby leading to less analgesic use, faster recovery and less time away from work. Adjuvant treatment may also reduce costly and invasive secondary treatments. Alpha‐blockers are particularly appealing for MET due to their reported favorable adverse effect profile and low cost. We expect this review to provide important guidance for individual patients, clinicians, guideline developers and policy makers by rigorously assessing the magnitude of both potential desirable and undesirable effects and our confidence in these estimates of effect. </p> <p>Existing systematic reviews on the use of MET after SWL to date have not applied the same methodological rigor as a Cochrane Review (<a href="./references#CD013393-bbs2-0109" title="LeeJK , JeongCW , JeongSJ , HongSK , ByunSS , LeeSE . Impact of tamsulosin on ureter stone expulsion in Korean patients: a meta-analysis of randomized controlled studies. Korean Journal of Urology2012;53(10):699-704.">Lee 2012</a>; <a href="./references#CD013393-bbs2-0110" title="LiM , WangZ , YangJ , GuoX , WangT , WangS , et al. Adjunctive medical therapy with alpha-blocker after extracorporeal shock wave lithotripsy of renal and ureteral stones: a meta-analysis. PloS One2015;10(4):e0122497.">Li 2015</a>; <a href="./references#CD013393-bbs2-0112" title="LosekRL , MauroLS . Efficacy of tamsulosin with extracorporeal shock wave lithotripsy for passage of renal and ureteral calculi. Annals of Pharmacotherapy2008;42(5):692-7.">Losek 2008</a>; <a href="./references#CD013393-bbs2-0134" title="SchulerTD , ShahaniR , HoneyRJ , PaceKT . Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: a systematic review and meta-analysis. Journal of Endourology2009;23(3):387-93.">Schuler 2009</a>; <a href="./references#CD013393-bbs2-0136" title="SeitzC , LiatsikosE , PorpigliaF , TiseliusHG , ZwergelU . Medical therapy to facilitate the passage of stones: what is the evidence?European Urology2009;56(3):455-71.">Seitz 2009</a>; <a href="./references#CD013393-bbs2-0141" title="SkolarikosA , GrivasN , KallidonisP , MourmourisP , RountosT , FiamegosA , et al. The efficacy of medical expulsive therapy (MET) in improving stone-free rate and stone expulsion time, after extracorporeal shock wave lithotripsy (SWL) for upper urinary stones: a systematic review and meta-analysis. Urology2015;86(6):1057-64.">Skolarikos 2015</a>; <a href="./references#CD013393-bbs2-0148" title="YangTX , LiaoBH , ChenYT , LiH , HeQ , LiuQY , et al. A network meta-analysis on the beneficial effect of medical expulsive therapy after extracorporeal shock wave lithotripsy. Scientific Reports2017;7(1):14429.">Yang 2017</a>; <a href="./references#CD013393-bbs2-0151" title="ZhengS , LiuLR , YuanHC , WeiQ . Tamsulosin as adjunctive treatment after shockwave lithotripsy in patients with upper urinary tract stones: a systematic review and meta-analysis. Scandinavian Journal of Urology and Nephrology2010;44(6):425-32.">Zheng 2010</a>), where we focus on patient‐centered outcomes by applying the GRADE approach (<a href="./references#CD013393-bbs2-0088" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , SchünemannHJ , et al. GRADE: what is "quality of evidence" and why is it important to clinicians?BMJ (Clinical Research Ed.)2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE]'>Guyatt 2008</a>). Our review is structured to address an ongoing knowledge gap on the effectiveness of MET after SWL in clinical practice. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013393-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013393-sec-0017"></div> <p>To assess the effects of alpha‐blockers as adjuvant medical expulsive therapy plus usual care compared to placebo and usual care or usual care alone in adults undergoing shock wave lithotripsy for renal or ureteral stones. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013393-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013393-sec-0018"></div> <section id="CD013393-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013393-sec-0020"> <h4 class="title">Types of studies</h4> <p>We included parallel group randomized controlled trials (RCTs). We included studies regardless of their publication status or language of publication. We considered that cross‐over trials were unsuitable for this review; also, cluster randomized controlled trials were also not relevant to this review question and therefore not considered. We excluded non‐RCTs and trials using pseudo‐randomization techniques as they are at greater risk of bias. </p> </section> <section id="CD013393-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included studies of men and non‐pregnant women (ages 18 years or older) of either gender who had undergone SWL for renal and ureteral stones. We included trials irrespective of the lithotripter type used, the number of shock waves applied and the number of sessions performed. We included only studies that use imaging to confirm stone diagnosis. The imaging modality may have been a single test – for example, NCCT – or a combination of tests such as KUB radiograph and ultrasound. </p> <p>We excluded studies on MET for the primary expulsion of stones. We also excluded studies of people with renal insufficiency (defined as an estimated glomerular filtration rate less than 60 ml/minute/1.73 m²), obstructive uropathy or UTI, as these represent contraindications for SWL.  </p> <p>If we identified studies in which only a subset of participants was relevant to this review, we included such studies if data were available separately for the relevant subset. </p> </section> <section id="CD013393-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We investigated the following comparisons of experimental intervention versus comparator intervention. Concomitant interventions had to be the same in the experimental and comparator groups to establish fair comparisons. </p> <section id="CD013393-sec-0023"> <h5 class="title">Experimental interventions</h5> <p> <ul id="CD013393-list-0001"> <li> <p>Alpha‐blockers as adjuvant medical expulsive therapy plus usual care.</p> </li> </ul> </p> </section> <section id="CD013393-sec-0024"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD013393-list-0002"> <li> <p>Placebo and usual care, or usual care alone.</p> </li> </ul> </p> </section> <section id="CD013393-sec-0025"> <h5 class="title">Comparisons</h5> <p> <ul id="CD013393-list-0003"> <li> <p>Alpha‐blockers as adjuvant medical expulsive therapy plus usual care versus placebo and usual care, or usual care alone. </p> </li> </ul> </p> <p>For the purpose of this review, usual care in the context of SWL for kidney and ureteral stones may have been used in the alpha‐blocker treatment group if the same care was also used in the control group. Usual care may have included oral or intravenous hydration, NSAIDs, pain medication and antibiotics as deemed clinically appropriate. We excluded studies that included antispasmodics, corticosteroids or herbal supplements in the usual care regimens as these could potentially alter the treatment effect; this approach was consistent with that of high‐quality reviews on MET (<a href="./references#CD013393-bbs2-0098" title="HollingsworthJM , CanalesBK , RogersMA , SukumarS , YanP , KuntzGM , et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ (Clinical Research Ed.)2016;355:i6112. [PMID: 27908918]">Hollingsworth 2016</a>). We recognized that this determination may have limited the applicability of our review findings with regard to practice settings in which these adjuvants are commonly used and limit further exploratory analyses as to their role. However, the main objectives of this study were the effects of alpha‐blockers, and inclusion of these adjuvants pose the risk of adding both noise (random error) and bias to the planned analysis. </p> <p>We anticipated potential variation in the intraoperative management of anesthetic, sedation, pain and antibiotics for people undergoing SWL, but did not consider those factors relevant unless they differed between treatment and control groups. </p> </section> </section> <section id="CD013393-sec-0026"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the measurement of the outcomes assessed in this review as an eligibility criterion. </p> <section id="CD013393-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013393-list-0004"> <li> <p>Stone clearance (dichotomous outcome).</p> </li> <li> <p>Auxiliary treatment (dichotomous outcome).</p> </li> <li> <p>Major adverse events (dichotomous outcome).</p> </li> </ul> </p> </section> <section id="CD013393-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013393-list-0005"> <li> <p>Quality of life (continuous outcome).</p> </li> <li> <p>Stone clearance time (continuous outcome).</p> </li> </ul> </p> <section id="CD013393-sec-0029"> <h6 class="title">Method and timing of outcome measurement</h6> <p>When reviewing outcomes, we considered clinically important differences by predefined thresholds to rate the overall quality of evidence in the 'Summary of findings' table (<a href="./references#CD013393-bbs2-0102" title="JaeschkeR , SingerJ , GuyattGH . Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials1989;10(4):407-15. [PMID: 2691207]">Jaeschke 1989</a>; <a href="./references#CD013393-bbs2-0103" title="JohnstonBC , PatrickDL , BusseJW , SchunemannHJ , AgarwalA , GuyattGH . Patient-reported outcomes in meta-analyses – Part 1: assessing risk of bias and combining outcomes. Health and Quality of Life Outcomes2013;11:109. [PMID: 23815754]">Johnston 2013</a>). In the absence of published minimal clinically important differences, we established thresholds with input from our content experts. </p> <section id="CD013393-sec-0030"> <p><b>Stone clearance</b></p> <p> <ul id="CD013393-list-0006"> <li> <p>Participants with documented passage of all stones from the kidney and ureter of a given size criterion based on imaging (e.g. KUB radiograph, NCCT) as defined by the investigators. </p> </li> <li> <p>We assessed this outcome up to 90 days after SWL.</p> </li> <li> <p>We considered a 5% absolute difference in stone clearance as clinically important.</p> </li> </ul> </p> </section> <section id="CD013393-sec-0031"> <p><b>Auxiliary treatment</b></p> <p> <ul id="CD013393-list-0007"> <li> <p>Participants requiring unplanned, additional treatments such as URS or stent placement due to failure of stones to pass or to treat secondary complications such ureteral colic or hydronephrosis. We did not consider additional SWL sessions as auxiliary treatment for this analysis. </p> </li> <li> <p>We assessed this outcome up to 30 days after SWL.</p> </li> <li> <p>We considered a 3% absolute difference in retreatment rates as clinically important.</p> </li> </ul> </p> </section> <section id="CD013393-sec-0032"> <p><b>Major adverse event</b></p> <p> <ul id="CD013393-list-0008"> <li> <p>Example: syncope or hypotension requiring hospitalization or unplanned emergency room visit. </p> </li> <li> <p>We used the Food and Drug Administration (FDA) definition of serious adverse events (<a href="./references#CD013393-bbs2-0084" title="US Food and Drug Administration. CFR – Code of Federal Regulations Title 21. Sec. 312.32 IND Safety Reporting. Part 312. Subpart B – Investigational New Drug Application (IND). Subchapter D – Drugs for Human Use. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm (accessed prior to 26 June 2019).">FDA 2018</a>). </p> </li> <li> <p>We assessed this outcome up to 90 days after SWL.</p> </li> <li> <p>We considered a 1% absolute difference in major adverse events rates as clinically important. </p> </li> </ul> </p> </section> <section id="CD013393-sec-0033"> <p><b>Quality of life</b></p> <p> <ul id="CD013393-list-0009"> <li> <p>Mean change from baseline or final mean value measured using a validated scale. For example, the RAND 36‐Item Short Form Health Survey (SF‐36) (<a href="./references#CD013393-bbs2-0146" title="Ware JE Jr, SherbourneCD . The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Medical Care1992;30(6):483-73.">Ware 1992</a>). </p> </li> <li> <p>We assessed this outcome up to 90 days after SWL.</p> </li> <li> <p>We considered a clinically important mean difference (MD) of points on quality of life scores based on the specific scale used. </p> </li> </ul> </p> </section> <section id="CD013393-sec-0034"> <p><b>Stone clearance time</b></p> <p> <ul id="CD013393-list-0010"> <li> <p>Length of time from onset of treatment to stone clearance (in participants who pass their stone) as measured in days. </p> </li> <li> <p>We considered an MD of one day as clinically important.</p> </li> </ul> </p> </section> </section> <section id="CD013393-sec-0035"> <h6 class="title">Main outcomes for 'Summary of findings' table</h6> <p>We presented a 'Summary of findings' table that reports on the following outcomes (listed according to priority). </p> <p> <ul id="CD013393-list-0011"> <li> <p>Stone clearance</p> </li> <li> <p>Auxiliary treatment</p> </li> <li> <p>Major adverse event</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Stone clearance time</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD013393-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed a comprehensive search with no restrictions on the language of publication or publication status. We reran searches within three months prior to anticipated publication of the review; the latest search date was 27 February 2020. </p> <section id="CD013393-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from inception of each database (<a href="./appendices#CD013393-sec-0123">Appendix 1</a>). </p> <p> <ul id="CD013393-list-0012"> <li> <p>Cochrane Library via Wiley:</p> <ul id="CD013393-list-0013"> <li> <p><i>Cochrane Database of Systematic Reviews</i> (CDSR); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE);</p> </li> <li> <p>Health Technology Assessment Database (HTA).</p> </li> </ul> </li> <li> <p>MEDLINE via PubMed (from 1946).</p> </li> <li> <p>Embase via Elsevier (from 1974).</p> </li> </ul> </p> <p>We also searched the following.</p> <p> <ul id="CD013393-list-0014"> <li> <p>ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> </li> <li> <p>Grey literature repository from the current Grey Literature Report (<a href="http://www.greylit.org/" target="_blank">www.greylit.org</a>). </p> </li> </ul> </p> <p>If detected additional relevant key words during any of the electronic or other searches, we modified the electronic search strategies to incorporate these terms and document the changes. </p> </section> <section id="CD013393-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, reviews, meta‐analyses and health technology assessment reports. We also contacted study authors of included trials to identify any further studies that we may have missed. We contacted drug/device manufacturers for ongoing or unpublished trials. We did not search abstract proceedings of relevant meetings, specifically those of the AUA, the EAU and the Endourological Society for the last three years (2017 to 2019; no meetings in 2020) separately for unpublished studies since the abstract proceedings for these meetings were included in our electronic searches. </p> </section> </section> <section id="CD013393-sec-0039"> <h3 class="title" id="CD013393-sec-0039">Data collection and analysis</h3> <section id="CD013393-sec-0040"> <h4 class="title">Selection of studies</h4> <p>We used the reference management software <a href="./references#CD013393-bbs2-0083" title="EndNote. Version 7.5. Philadelphia (PA): Clarivate Analytics, 2016.">EndNote</a> to identify and remove potential duplicate records. Two review authors (MO, RV or NS) independently scanned the abstract, title, or both, of remaining records retrieved, to determine which studies should be assessed further using <a href="./references#CD013393-bbs2-0076" title="Veritas Health InnovationCovidence. Version accessed 30 April 2020. Melbourne, Australia: Veritas Health Innovation, N/A. Available at covidence.org.">Covidence</a> software. Two review authors (MO, RV or NS) independently investigated all potentially relevant records as full text, mapped records to studies, and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies in accordance with the criteria for each provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013393-bbs2-0094" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). We resolved any discrepancies through consensus or recourse to a third review author (PD). If resolution was not possible, we designated the study as 'awaiting classification' and we contacted study authors for clarification. We documented reasons for exclusion of studies that may have reasonably been expected to be included in the review in the <a href="./references#CD013393-sec-0134" title="">Characteristics of excluded studies</a> table. We presented an adapted PRISMA flow diagram showing the process of study selection (<a href="./references#CD013393-bbs2-0111" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). </p> </section> <section id="CD013393-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data abstraction form that we pilot tested.</p> <p>For studies that fulfilled inclusion criteria, two review authors (MO, RV or NS) independently abstracted the following information, which we provided in the <a href="./references#CD013393-sec-0133" title="">Characteristics of included studies</a> table. </p> <p> <ul id="CD013393-list-0015"> <li> <p>Study design.</p> </li> <li> <p>Study dates (if dates were not available then we reported as such).</p> </li> <li> <p>Study settings and country.</p> </li> <li> <p>Type of lithotripter device used and target size for stone fragments.</p> </li> <li> <p>Participant inclusion and exclusion criteria (i.e. stone size, stone location).</p> </li> <li> <p>Participant details, baseline demographics (i.e. participant age, stone size, stone location, laterality). </p> </li> <li> <p>Procedure details (i.e. mean number of shock waves administered, number of session).</p> </li> <li> <p>Number of participants by study and study arm.</p> </li> <li> <p>Details of relevant experimental and comparator interventions (i.e. type of alpha‐blocker, dosage, duration of treatment in weeks). </p> </li> <li> <p>Definitions of relevant outcomes, and method and timing of outcome measurement as well as any relevant subgroups. </p> </li> <li> <p>Imaging modality used to assess stone clearance (i.e. KUB radiograph, ultrasound, NCCT). </p> </li> <li> <p>Study funding sources.</p> </li> <li> <p>Declarations of interest by primary investigators.</p> </li> </ul> </p> <p>We extracted outcome data relevant to this Cochrane Review as needed for calculation of summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events and totals for population of a 2 × 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations or data necessary to calculate this information. </p> <p>We resolved any disagreements by discussion, or, if required, by consultation with a third review author (PD). </p> <p>We provided information, including trial identifier, about potentially relevant ongoing studies in the Characteristics of ongoing studies table. </p> <p>We attempted to contact authors of included studies to obtain key missing data as needed. </p> <section id="CD013393-sec-0042"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary study, we maximized yield of information by mapping all publications to unique studies and collating all available data. We collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We used the most complete data set aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD013393-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (MO, RV, NS) independently assessed the risk of bias of each included study. We resolved disagreements by consensus, or by consultation with a third review author (PD). </p> <p>We assessed risk of bias using Cochrane's 'Risk of bias' assessment tool (<a href="./references#CD013393-bbs2-0096" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We assessed the following domains. </p> <p> <ul id="CD013393-list-0016"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We judged risk of bias domains as 'low risk', 'high risk' or 'unclear risk' and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013393-bbs2-0096" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We presented a 'Risk of bias' summary figure to illustrate these findings. </p> <p>For performance bias (blinding of participants and personnel), we considered all outcomes similarly susceptible to performance bias. </p> <p>For detection bias (blinding of outcome assessment), we grouped outcomes as susceptible to detection bias (investigator or participant assessed) or not susceptible to detection bias (objective). </p> <p>We defined the following endpoints as investigator assessed outcomes.</p> <p> <ul id="CD013393-list-0017"> <li> <p>Stone clearance.</p> </li> <li> <p>Major adverse events.</p> </li> <li> <p>Stone clearance time.</p> </li> </ul> </p> <p>We defined the following endpoint as a participant assessed outcome.</p> <p> <ul id="CD013393-list-0018"> <li> <p>Quality of life.</p> </li> </ul> </p> <p>We defined the following endpoint as an objective outcome.</p> <p> <ul id="CD013393-list-0019"> <li> <p>Auxiliary treatments.</p> </li> </ul> </p> <p>We assessed attrition bias (incomplete outcome data) on an outcome specific basis and presented the judgment for each outcome separately when reporting our findings in the 'Risk of bias' tables. </p> <p>We further summarized the risk of bias across domains for each outcome in each included study, as well as across studies and domains for each outcome, in accordance with the approach for summary assessments of the risk of bias presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013393-bbs2-0096" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). </p> </section> <section id="CD013393-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We expressed continuous data as mean differences (MDs) with 95% CIs unless studies use different measures to assess the same outcome, in which case we expressed data as standardized mean differences with 95% CIs. We expressed time‐to‐event data as hazard ratios (HRs) with 95% CIs. </p> </section> <section id="CD013393-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant and we accounted for the level at which randomization occurred. If we identified trials with more than two intervention groups for inclusion in the review, we handled these in accordance with guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013393-bbs2-0095" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). </p> </section> <section id="CD013393-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We obtained missing data from study authors, if feasible, and performed intention to treat (ITT) analyses if data were available; we otherwise performed available case analyses but identified the analysis as such. We investigated attrition rates (e.g. dropouts, losses to follow‐up and withdrawals), and critically appraised issues of missing data. We did not impute missing data. </p> </section> <section id="CD013393-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of excessive heterogeneity unexplained by subgroup analyses, we did not report outcome results as the pooled effect estimate in a meta‐analysis but provided a narrative description of the results of each study. </p> <p>We identified heterogeneity (inconsistency) through visual inspection of the forest plots to assess the amount of overlap of CIs, and the I² statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD013393-bbs2-0092" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [DOI: 10.1002/sim.1186]">Higgins 2002</a>; <a href="./references#CD013393-bbs2-0093" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.)2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557]">Higgins 2003</a>); we interpreted the I² statistic as follows (<a href="./references#CD013393-bbs2-0080" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> <p> <ul id="CD013393-list-0020"> <li> <p>0% to 40%: may not be important.</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When we found heterogeneity, we attempted to determine possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD013393-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting.</p> <p>If we included 10 studies or more investigating a particular outcome, we used funnel plots to assess small study effects. Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias. Therefore, we interpreted results carefully. </p> </section> <section id="CD013393-sec-0049"> <h4 class="title">Data synthesis</h4> <p>Unless there was good evidence for homogeneous effects across studies, we summarized data using a random‐effects model. We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. In addition, we performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013393-bbs2-0094" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method and for continuous outcomes, we used the inverse variance method. We used Review Manager 5 software to perform analyses (<a href="./references#CD013393-bbs2-0124" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD013393-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity and planned to carry out subgroup analyses with investigation of interactions. </p> <p> <ul id="CD013393-list-0021"> <li> <p>Stone location (renal or proximal ureter versus distal ureter).</p> </li> <li> <p>Stone size (less than 10 mm versus 10 mm or greater).</p> </li> <li> <p>Specific alpha‐blocker (e.g. terazosin versus doxazosin).</p> </li> <li> <p>Type of lithotripter (HM3 versus others)</p> </li> </ul> </p> <p>The subgroup analyses by stone location, size and type of alpha‐blocker were based on observations of potential subgroup effects demonstrated in previous studies for the use of MET for ureteral colic (<a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a>; <a href="./references#CD013393-bbs2-0098" title="HollingsworthJM , CanalesBK , RogersMA , SukumarS , YanP , KuntzGM , et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ (Clinical Research Ed.)2016;355:i6112. [PMID: 27908918]">Hollingsworth 2016</a>; <a href="./references#CD013393-bbs2-0123" title="PremingerGM , TiseliusHG , AssimosDG , AlkenP , BuckC , GallucciM , et al. 2007 Guideline for the management of ureteral calculi. Journal of Urology2007;178(6):2418-34. [PMID: 17993340]">Preminger 2007</a>). The subgroup analysis based on type of lithotripter was based on the fact that different shock wave lithotripter devices vary in their effectiveness in stone fragmentation with the HM3 lithotripter (as first generation lithotripter with the largest acoustic energy focal zone) being the most powerful in achieving stone fragmentation (<a href="./references#CD013393-bbs2-0115" title="McClainPD , LangeJN , AssimosDG . Optimizing shock wave lithotripsy: a comprehensive review. Reviews in Urology2013;15(2):49-60.">McClain 2013</a>). </p> <p>In addition, we performed post hoc analyses that were suggested by one of the peer reviewers and were based on a different categorization of stone location. The underlying rationale was that the targeted alpha‐1 receptors are primarily found in the ureteral (not renal pelvis), predominantly in its distal part <a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a>; <a href="./references#CD013393-bbs2-0098" title="HollingsworthJM , CanalesBK , RogersMA , SukumarS , YanP , KuntzGM , et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ (Clinical Research Ed.)2016;355:i6112. [PMID: 27908918]">Hollingsworth 2016</a>, therefore raising the possibility of a reduced effect in renal stones.  </p> <p> <ul id="CD013393-list-0022"> <li> <p>Stone location (renal or ureter).</p> </li> </ul> </p> <p>We used the test for subgroup differences in Review Manager 5 to compare subgroup analyses if there were sufficient studies (<a href="./references#CD013393-bbs2-0124" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We limited subgroup analyses to primary outcomes only. </p> </section> <section id="CD013393-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses, limited to the primary outcomes, in order to explore the influence of the following factors (when applicable) on effect sizes. </p> <p> <ul id="CD013393-list-0023"> <li> <p>Restricting the analysis by considering risk of bias, by excluding studies at 'high risk' or 'unclear risk'. </p> </li> <li> <p>Limiting the analysis to studies with a documented single SWL session and studies with multiple SWL sessions that reported outcomes separately by the number of sessions (thereby allowing us to focus on the results of a single session only). </p> </li> </ul> </p> </section> <section id="CD013393-sec-0052"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We present the overall certainty of evidence for each outcome according to the GRADE approach, which takes into account five criteria related to internal validity (risk of bias, inconsistency, imprecision, publication bias), and external validity, such as directness of results (<a href="./references#CD013393-bbs2-0088" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , SchünemannHJ , et al. GRADE: what is "quality of evidence" and why is it important to clinicians?BMJ (Clinical Research Ed.)2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE]'>Guyatt 2008</a><i>).</i> GRADE has good interobserver agreement when used by trained individuals (<a href="./references#CD013393-bbs2-0117" title="MustafaRA , SantessoN , BrozekJ , AklEA , WalterSD , NormanG , et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology2013;66(7):736-42; quiz 742 e1-5.">Mustafa 2013</a>). For each comparison, two review authors (MO, RV or NS) independently rated the certainty of evidence for each outcome as 'high', 'moderate', 'low' or 'very low' using <a href="./references#CD013393-bbs2-0086" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 30 April 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), N/A. Available at gradepro.org.">GRADEpro GDT</a>. We resolved any discrepancies by consensus or, if needed, by arbitration by a third review author (PD). For each comparison, we presented a summary of the evidence for the main outcomes in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD013393-bbs2-0089" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026]">Guyatt 2011</a>; <a href="./references#CD013393-bbs2-0135" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. Chapter 11: Completing 'Summary of findings' tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017</a>). If meta‐analysis had not been possible, we would have presented the results in a narrative 'Summary of findings' table. We applied a partially conceptualized approach defining a minimally clinically important difference that was based on the published literature or the input of clinical expertise of the coauthors, or both (<a href="./references#CD013393-bbs2-0100" title="HultcrantzM , RindD , AklEA , TreweekS , MustafaRA , IorioA , et al. The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology2017;87:4-13.">Hultcrantz 2017</a>). We used GRADE guidance to describe both the certainty of evidence and the magnitude of the effect size (<a href="./references#CD013393-bbs2-0130" title="SantessoN , GlentonC , DahmP , GarnerP , AklEA , AlperB , et al, GRADE Working Group. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35.">Santesso 2020</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013393-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013393-sec-0053"></div> <section id="CD013393-sec-0054"> <h3 class="title">Description of studies</h3> <p>Our comprehensive literature search identified 412 records. We found no applicable records in trials registers or the grey literature repository. </p> <section id="CD013393-sec-0055"> <h4 class="title">Results of the search</h4> <p>After duplicates were removed, we screened the titles and abstracts of 249 records, and excluded 181 records. We screened 74 full text records (65 studies) and excluded 27 records (25 studies) for the reasons given in the <a href="./references#CD013393-sec-0134" title="">Characteristics of excluded studies</a> table. We included 47 records (40 studies) in the systematic review. There were no ongoing studies that met inclusion criteria. The details of the literature search are shown in the PRISMA flowchart (<a href="#CD013393-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013393-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013393-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013393-sec-0056"> <h4 class="title">Included studies</h4> <p>We presented details of the included studies in the <a href="./references#CD013393-sec-0133" title="">Characteristics of included studies</a> table, <a href="#CD013393-tbl-0002">Table 1</a>, and <a href="#CD013393-tbl-0003">Table 2</a>. </p> <div class="table" id="CD013393-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial period (year to year)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Setting/country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SWL description (lithotripter; number shocks; power setting)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number SWL sessions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Stone location (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Largest stone size (mm, mean ± SD)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single upper ureteric stone &lt; 15 mm in size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Lithostar Multiline; max 3500 shocks; 14.4–15.1 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 ± 1.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (NSAIDs, antispasmodics, or tramadol PRN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 ± 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2013–2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Saudi Arabia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Solitary renal stone &lt; 20 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Dornier SII; max 3500 shocks; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.06 ± 3.82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac potassium 50 mg BID for 2 days, additional doses PRN; drink plenty of fluids) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.56 ± 3.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009–2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal colic and upper ureteral stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Siemens Lithoscope; max 3000 shocks; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin 4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.06 ± 1.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium PRN; drink fluid to provide urine output ≥ 2 L/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 ± 2.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal calculi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin 10 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (standard analgesia PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004–2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single radiopaque renal 6–24 mm or ureteral 6–15 mm calculus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dornier Compact S Lithotripter; 1,500 shocks; 14–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 calyx/6 pelvis/5 upper renal/4 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (proxyvon [65 mg dextropropoxyphene hydrochloride and 400 mg acetaminophen] daily PRN; minimum 2.5 L fluids) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 calyx/9 pelvis/6 upper renal/2 lower ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008–2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Solitary 6–15 mm ureteral stone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Storz Medical AG Modulith Slk; 2700–3600 shocks; 6–19 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.4 ± 3.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 75 mg IM PRN, pantoprazole 40 mg/day, after discharge drink 2 L water daily) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7 ± 3.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal stones undergoing ESWL up to 3 times</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (analgesic not further defined)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with radio‐opaque ureter stones 5–10 mm in diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comed Lithotripsy SDS‐5000; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin 10 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 upper ureteral/6 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 ± 1.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (loxoprofen sodium 68.1 mg PRN; 2 L fluids daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 upper ureteral/6 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 ± 1.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2012–2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Presumed single center/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single radiopaque renal stone (0.5–2 cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>EDAP integrated Sonolith 4000 plus; max 3500 shocks; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 upper renal/7 mid‐renal/5 lower renal/5 pelvis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.28 ± 2.46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care not further defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 upper renal/6 mid‐renal/2 lower renal/9 pelvis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.23 ± 2.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 8 mg/day +  usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 upper renal/4 mid‐renal/9 lower renal/4 pelvis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.45 ± 1.73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Presumed single center/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single radio‐opaque renal or upper ureteral stones ≤ 2 cm in largest diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months or until stone free</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic Siemens Lithostar; max 4000 shocks; 14–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 renal (5 upper calyx/3 mid‐calyx/12 lower calyx/15 pelvis)/28 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 ± 1.8 renal, 9.7 ± 2.6 ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (sodium diclofenac 50 mg oral or 75 mg IM PRN) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 renal (4 upper calyx/6 mid‐calyx/14 lower calyx/18 pelvis)/21 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 ± 2.3 renal, 8.6 ± 1.7 ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Presumed single center/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 to 10 mm single radio‐opaque upper ureteral stones (above iliac vessels)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotriptor Compact Sigma; max 4000 shocks; 14–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium, enteric‐coated tablets 75 mg PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008–2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal or ureteral stone 4–20 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Storz lithotriptor; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 renal/9 ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.22 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (ofluxacine 200 mg per 12 hours for 5 days; minimum 2 L fluid daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 renal/14 ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.88 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Solitary renal pelvic calculi who were successfully fragmented by ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium 75 mg PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazocin daily for up to 12 weeks + usual care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5–20 mm ureteric stone in any position</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (analgesic not further specified 1 week PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Males with solitary, radio‐opaque upper urinary tract stones, ≤ 20 mm in the max diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks after last SWL session</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 renal/12 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 ± 4.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (drink liberal fluids, analgesic not further specified PRN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 renal/10 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 ± 4.82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral stone 6–12 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Piezolith‐3000; 3000 shocks; 15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (drink 2 L fluid daily)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Singapore</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteric or renal stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin XL 10 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 renal/8 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care only (not further described)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 renal/7 upper ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Males with ureteral stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 0.8 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (pain relieving therapy)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Presumed single center/Morocco</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral stones undergoing ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Storz MODULITH SLX‐F2; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 upper calyx/23 mid‐calyx/79 pelvis/54 lumbar ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 ± 2.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 25 mg TID; minimum 2 L water daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 upper calyx/19 mid‐calyx/75 pelvis/50 lumbar ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 ± 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≥ 4 mm ureteral stone with acute pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Compact Delta II, E‐3000, Sonolith Praktis; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg and diclofenac 100 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 renal/50 upper ureteral/47 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 renal/34 upper ureteral/39 lower ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≤ 10 mm upper and lower ureteral stone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sonolith Praktis; 2500–3000 shocks; 10–18 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg and pethidine 50 mg IV (once during SWL) + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 upper ureteral/24 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Education for hydration and exercise + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 upper ureteral/13 lower ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Males with ureteral stones &gt; 4 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Until stone clearance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dornier lithotripter, Stoltz SLX‐MX, Simens modularis variostar; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 proximal ureteral/3 mid‐ureteral/8 distal ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.61 ± 4.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 50 mg suppository PRN; 2 L water per day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 proximal ureteral/3 mid‐ureteral/8 distal ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.85 ± 3.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0023" title="KüpeliB , IrkilataL , GürocakS , TunçL , KiraçM , KaraoglanU , et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?Urology2004;64(6):1111-5. ">Küpeli 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2003–2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral stones within the distal 5 cm of the ureter 3–15 mm in size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Siemens Lithostar Plus; 2000–3500 shocks; 18.7 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium 100 mg/day for 15 days; oral hydration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with urinary stone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin or silodosin + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 renal/24 ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (analgesic PRN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 renal/26 ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single ureteral stone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (hydration, antibiotics, acetaminophen PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2003–2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Radiopaque or radiolucent ureteral lithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dornier Lithotripter S; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg; ketoprofene 50 mg BID for 7 days + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 ± 2.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 75 mg IM PRN; 1.5–2 L water daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 ± 1.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Solitary ureteric stone 5–15 mm diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Dornier SII; max 3000–4000 shocks; 12–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 upper ureteral/14 mid‐ureteral/26 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (furosemide 20 mg every morning; diclofenac sodium 50 mg TID or a 75 mg ampoule PRN; oral fluids) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 upper ureteral/13 mid‐ureteral/21 lower ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single radiopaque renal stone (5–20 mm) undergoing ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Siemens Lithostar‐Multiline; max 3500 shocks; 13.4–15.1 kV </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 renal pelvis/9 superior calyx/4 middle calyx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.12 ± 3.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (NSAIDs, antispasmodics or tramadol PRN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 renal pelvis/7 superior calyx/6 middle calyx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.06 ± 3.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011–2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages 18–70 years with symptomatic, unilateral and single proximal ureteral stones 6–20 mm in the longest axis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sonolith Praktis electroconductive lithotripter EDAP TMS S.A.; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proximal ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (aceclofenac 100 mg PRN; 1.5–2 L water daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single radio‐opaque renal stone (0.5–2.0 cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic shock wave generator Storz Medical Modulith SLK; max 4000 shocks; max 70 kV </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 pelvis/17 lower renal/5 mid‐renal/2 upper renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2 ± 3.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium 50 mg BID for 1 day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 pelvis/13 lower renal/3 mid‐renal/1 upper renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 ± 2.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Inclusion criteria for ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin (dose NR) + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (not further defined)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ureteral stones &lt; 10 mm treated with ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (not further defined)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0033" title="ShaikhAA , PatujoYH , ShaikhAB , ShaikhNA , JalbaniMH . Comparison of efficacy with and without tamsulosin as medical adjuvant therapy after extracorporeal shockwave lithotripsy in renal stone. Rawal Medical Journal2018;43(3):471-4. ">Shaikh 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages &gt; 18 to &lt; 50 years, single radio‐opaque and size &lt; 20 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg  + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 ± 2.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 50 mg BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.61 ± 3.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009 to NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Apparent ESWL‐fragmentation of renal stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin (dose NR) + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 ± 4.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (not further defined)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1 ± 2.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages ≥ 18 years with symptomatic, unilateral, solitary lower ureteric calculus 4–12 mm in major axis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter HK–ESWL–VI; max 3000 shocks; 12–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (antibiotics and diclofenac PRN during the study period; 2500 mL fluid daily) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages 18–70 years with symptomatic, unilateral and solitary upper ureteral calculi 6–15 mm in major axis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter HK–ESWL–VI; max 3000 shocks; 12–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac PRN during the study period; 2500 mL fluid daily)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single center/Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>7–19 mm stone diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 100 mg suppositories daily; diclofenac 25 mg) orally</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin 2 mg + usual care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2012–2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants who underwent successful SWL (fragments &lt; 4 mm) for single renal stone ≤ 2 cm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (analgesic and anti‐inflammatory)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages &gt; 18 years, radio‐opaque non‐lower pole renal stone (5–20 mm) and ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Dornier Compact Delta Lithotriptor; 4000 shocks; 11–14 kV </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 superior calyx/13 mid‐calyx/14 pelvis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (celecoxib 200 mg BID PRN; 3 L liquid daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 superior calyx/16 mid‐calyx/15 pelvis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6 ± 2.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (not further defined)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± 3.1</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BID: twice daily; ESWL: extracorporeal shock wave lithotripsy; IM: intramuscular; IV: intravenous; max: maximum; n: number; NR: not reported; NSAID: non‐steroidal anti‐inflammatory drug; PRN: on demand; SD: standard deviation; SWL: shock wave lithotripsy; TID: three times daily. </p> </div> </div> <div class="table" id="CD013393-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included studies and imaging modality used to assess stone clearance</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomized (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analyzed (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial (n [%])</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up imaging modality</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB</p> <p> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs, antispasmodics or tramadol PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>326/279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (91.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB, ultrasound and CT<br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac potassium 50 mg BID for 2 days, additional doses PRN; drink plenty of fluids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 (92.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249 (91.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p> KUB<br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium PRN; drink fluid to provide urine output ≥ 2 L/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (NR)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 (87.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard analgesia on demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p> KUB<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proxyvon (dextropropoxyphene hydrochloride 65 mg and acetaminophen 400 mg ) daily PRN; minimum 2.5 L fluids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (96.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 75 mg IM on demand, pantoprazole 40 mg/day, after discharge drink 2 L water daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (NR)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analgesic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (91.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loxoprofen sodium 68.1 mg PRN; 2 L fluids daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (95.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (93.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ultrasound and CT<br/> <br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 8 mg/day for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (90.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sodium diclofenac 50 mg oral or 75 mg IM PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium, enteric‐coated tablets 75 mg PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (67.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (93.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ofluxacine 200 mg per 12 hours for 5 days; minimum 2 L fluid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 (94.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium 75 mg PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazocin daily for up to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analgesic 1 week PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drink liberal fluids, analgesic PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p> KUB and IVP</p> <p> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drink 2 L fluid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin XL 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 0.8 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain relieving therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB, ultrasound and CT<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 25 mg TID; minimum 2 L water daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg and diclofenac 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg and pethidine 50 mg IV (once during SWL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB, IVP or CT<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Education for hydration and exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 50 mg suppository PRN; 2 L water per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0023" title="KüpeliB , IrkilataL , GürocakS , TunçL , KiraçM , KaraoglanU , et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?Urology2004;64(6):1111-5. ">Küpeli 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and CT<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium 100 mg/day for 15 days; oral hydration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin or silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analgesic PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative therapy PRN, e.g. hydration, antibiotics, acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg; ketoprofene 50 mg BID for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB, ultrasound and CT<br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 75 mg IM PRN; 1.5–2 L water daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>156/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Furosemide 20 mg every morning; diclofenac sodium 50 mg TID or a 75 mg ampoule PRN; oral fluids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (76.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs, antispasmodics or tramadol PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (90.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (83.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (91.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aceclofenac 100 mg PRN; 1.5–2 L water daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (91.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (91.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium 50 mg BID for 1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin (dose NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0033" title="ShaikhAA , PatujoYH , ShaikhAB , ShaikhNA , JalbaniMH . Comparison of efficacy with and without tamsulosin as medical adjuvant therapy after extracorporeal shockwave lithotripsy in renal stone. Rawal Medical Journal2018;43(3):471-4. ">Shaikh 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 50 mg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin (dose NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound      <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics and diclofenac PRN during the study period; 2500 mL fluid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (98.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (99.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac PRN during the study period; 2500 mL fluid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (NR)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (97.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR<br/> <br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 100 mg suppositories daily; diclofenac 25 mg orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analgesic and anti‐inflammatory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (84.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Celecoxib 200 mg BID PRN; 3 L liquid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (82.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (83.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (100)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BID: twice daily; CT: computer tomography; IM: intramuscular; IV: intravenous; IVP: intravenous pyelography; KUB: kidney, ureter, bladder radiograph; n: number; NR: not reported; NSAID: non‐steroidal anti‐inflammatory drug; PRN: on demand; SWL: shock wave lithotripsy; TID: three times daily. </p> </div> </div> <section id="CD013393-sec-0057"> <h5 class="title">Source of data</h5> <p>We included 26 studies published in full text and 14 as abstract proceedings (<a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a>; <a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a>; <a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a>; <a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a>; <a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a>; <a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a>; <a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a>; <a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>; <a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>; <a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a>; <a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a>). Most studies were published in English; three were in Korean (<a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a>; <a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a>; <a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a>), and one in Chinese (<a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a>). The Korean studies were translated by a review author (ECH) and we used Google translator for the Chinese study. We attempted to contact all corresponding authors of included trials to obtain additional information on study methodology and results and received replies from only a few. Details of this communication are provided in the notes section of the <a href="./references#CD013393-sec-0133" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD013393-sec-0058"> <h5 class="title">Study design and settings</h5> <p>We included all parallel RCTs. Only four studies were described as 'double blind' (<a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a>; <a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>). One study was reported as single blind, but it was unclear who was blinded (<a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a>). It was unclear if blinding was performed in five studies (<a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a>; <a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a>; <a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a>; <a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a>). The remaining 30 studies were open label. </p> <p>Studies were performed in both inpatient and outpatient centers. Four studies were in the hospital setting (<a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a>; <a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a>; <a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a>). Eight studies were in an outpatient setting (<a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a>; <a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a>; <a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a>; <a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>; <a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>; <a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>). Two studies reported they were performed specifically in an SWL center (<a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a>; <a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a>). Most studies were performed in Asia (China, India, Iran, Japan, Korea, Pakistan, Saudi Arabia, Singapore and Turkey), but also in Africa (Egypt and Morocco), Europe (France and Italy) and South America (Brazil). Four trials were multicenter (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a>; <a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a>). The studies were performed from 2003 to 2015. </p> </section> <section id="CD013393-sec-0059"> <h5 class="title">Participants</h5> <p>We included 4793 randomized participants, of whom 3087 completed the trials. However, six studies did not clearly report the number randomized to each group (<a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a>; <a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>), and 12 studies did not clearly report the number completing the trial in each group (<a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a>; <a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a>; <a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a>; <a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a>; <a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a>; <a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>; <a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>; <a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a>; <a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a>). The mean age of participants was 28.6 years to 56.8 years. Twelve studies did not report participants' age (<a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a>; <a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a>; <a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a>; <a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a>; <a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a>; <a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a>; <a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>; <a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>; <a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a>). As reported in <a href="#CD013393-tbl-0002">Table 1</a>, studies used a variety of lithotripters but no study used the Dornier HM3 device (thereby precluding one of our predefined subgroup analyses). </p> <p>The mean size of stones prior to SWL was 7.1 mm to 13.2 mm. Twelve studies did not report stone size (<a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a>; <a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a>; <a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a>; <a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a>; <a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a>; <a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a>; <a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>; <a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>; <a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a>). The stone location for 12 studies was ureteral (<a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a>; <a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a>; <a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a>; <a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a>; <a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a>; <a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a>; <a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>; <a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>; <a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a>). In 11 it was renal (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a>; <a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a>; <a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a>; <a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a>; <a href="./references#CD013393-bbs2-0033" title="ShaikhAA , PatujoYH , ShaikhAB , ShaikhNA , JalbaniMH . Comparison of efficacy with and without tamsulosin as medical adjuvant therapy after extracorporeal shockwave lithotripsy in renal stone. Rawal Medical Journal2018;43(3):471-4. ">Shaikh 2018</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>; <a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>). Six studies specified only upper ureteral stones (<a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a>; <a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a>; <a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a>; <a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>). Four studies included only lower ureteral stones (<a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a>; <a href="./references#CD013393-bbs2-0023" title="KüpeliB , IrkilataL , GürocakS , TunçL , KiraçM , KaraoglanU , et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?Urology2004;64(6):1111-5. ">Küpeli 2004</a>; <a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a>; <a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a>). Three studies included renal and ureteral stones (<a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a>; <a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a>). An additional three studies included renal and upper ureteral stones (<a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a>; <a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a>; <a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a>). One study did not report on stone location (<a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a>). </p> </section> <section id="CD013393-sec-0060"> <h5 class="title">Interventions, comparators and comparisons</h5> <p>Twenty‐seven of 40 studies used tamsulosin. The dosage of tamsulosin was typically 0.4 mg daily, but seven studies used 0.2 mg daily (<a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a>; <a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a>; <a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a>; <a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>; <a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>). Two studies did not report the dosage (<a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>). Three studies compared tamsulosin directly to another alpha‐blocker: to silodosin (<a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>), doxazosin (<a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a>), and terazosin (<a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a>). One study used either tamsulosin or silodosin (<a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a>). Three studies used alfuzosin (<a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a>; <a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a>; <a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a>). One study used doxazosin (<a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>) and one used silodosin (<a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a>). </p> <p>The standard therapies for comparators in 23/40 studies included NSAIDs, and diclofenac was the most frequently used. Nineteen of 40 studies included counseling about general fluid intake or to a specific urine output goal (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a>; <a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a>; <a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a>; <a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a>; <a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a>; <a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a>; <a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a>; <a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a>; <a href="./references#CD013393-bbs2-0023" title="KüpeliB , IrkilataL , GürocakS , TunçL , KiraçM , KaraoglanU , et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?Urology2004;64(6):1111-5. ">Küpeli 2004</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>; <a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>; <a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>; <a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>). Seven studies used an unspecified analgesia as the comparator (<a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a>; <a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a>; <a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a>; <a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a>; <a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a>; <a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a>; <a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a>). Three studies used narcotic pain medications (<a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a>; <a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a>). Two studies used acetaminophen as a pain reliever (<a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>). Four studies potentially used antibiotics as part of standard therapy (<a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a>; <a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a>; <a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>). One study used a diuretic in the comparator group (<a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>). Six studies used no alpha‐blocker as the comparator group and did not provide further details (<a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a>; <a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>; <a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a>). The duration of follow‐up ranged from two weeks to 12 weeks or until stone free. </p> </section> <section id="CD013393-sec-0061"> <h5 class="title">Outcomes</h5> <p>We identified the primary outcome of stone clearance in 36 of 40 studies. We found fewer studies with data on the other primary outcomes auxiliary treatment (12/40), major adverse events (7/40) and the secondary outcome of stone clearance time (14/40). We identified no studies reporting on participants' quality of life. </p> <p>The modality of follow‐up imaging was frequently not reported (18/40 studies; <a href="#CD013393-tbl-0003">Table 2</a>). When reported, it was based on KUB alone (5/40), KUB and ultrasound (10/40), or other combinations such as KUB plus intravenous pyelography or computer tomography imaging (7/40). </p> </section> <section id="CD013393-sec-0062"> <h5 class="title">Funding sources and conflicts of interest</h5> <p>Two studies reported no funding source (<a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>). One study reported funding from an industry grant (<a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>). The funding source in the remaining studies was not reported. Twelve studies reported no conflicts of interest (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a>; <a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a>; <a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a>; <a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>; <a href="./references#CD013393-bbs2-0033" title="ShaikhAA , PatujoYH , ShaikhAB , ShaikhNA , JalbaniMH . Comparison of efficacy with and without tamsulosin as medical adjuvant therapy after extracorporeal shockwave lithotripsy in renal stone. Rawal Medical Journal2018;43(3):471-4. ">Shaikh 2018</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>; <a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>). One study reported an industry grant as a conflict of interest (<a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>). The remaining studies did not report on conflicts of interest. The funding source and conflict of interest status was not identifiable for one study due to the language of publication (<a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a>). </p> </section> </section> <section id="CD013393-sec-0063"> <h4 class="title">Excluded studies</h4> <p>We excluded 25 studies after evaluation of the full text articles. For details, see <a href="./references#CD013393-sec-0134" title="">Characteristics of excluded studies</a> table. Common reason for exclusion were wrong patient population, and wrong intervention or comparison. We also found several trials that had been aborted without any results. </p> <section id="CD013393-sec-0064"> <h5 class="title">Studies awaiting classification</h5> <p>We identified no studies awaiting classification.</p> </section> <section id="CD013393-sec-0065"> <h5 class="title">Ongoing studies</h5> <p>We identified no ongoing studies.</p> </section> </section> </section> <section id="CD013393-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed risk of bias using the following domains as summarized in <a href="#CD013393-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD013393-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD013393-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013393-sec-0067"> <h4 class="title">Allocation</h4> <p>Nineteen studies described the method of random sequence generation; the remaining studies did not describe the method of random sequence generation and were judged at unclear risk of bias. </p> <p>With regard to allocation concealment, one study described the use of alternating group assignment, which we judged as an inappropriate method of allocation concealment (<a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a>). Only one study reported centralized randomization and was rated as low risk of bias in this domain (<a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a>); all other studies (38/40) did not address the issue of allocation concealment and we rated them at unclear risk of bias. </p> </section> <section id="CD013393-sec-0068"> <h4 class="title">Blinding</h4> <section id="CD013393-sec-0069"> <h5 class="title">Performance bias</h5> <p>Thirty‐one studies were clearly identifiable as open label studies that did not blind participants or personnel. Only four studies described appropriate methods of blinding and were judged as low risk for performance bias (<a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a>; <a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>). The remaining studies had an unclear risk of bias. </p> </section> <section id="CD013393-sec-0070"> <h5 class="title">Detection bias</h5> <p>We assessed the risk of detection bias on a per outcome basis.</p> <section id="CD013393-sec-0071"> <h6 class="title">Stone clearance</h6> <p>This was an investigator assessed outcome that required judgment and, therefore, was viewed as an outcome for which blinding of outcome assessors was important. Twenty‐eight studies were likely to have not blinded outcome assessors and were, therefore, rated as high risk. Only three studies provided assurance that outcome assessors were blinded and were rated as low risk (and informed our predefined sensitivity analyses; see <a href="./references#CD013393-fig-0023" title="">Analysis 6.1</a>; <a href="./references#CD013393-fig-0024" title="">Analysis 6.2</a>; and <a href="./references#CD013393-fig-0025" title="">Analysis 6.3</a>) (<a href="./references#CD013393-bbs2-0023" title="KüpeliB , IrkilataL , GürocakS , TunçL , KiraçM , KaraoglanU , et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?Urology2004;64(6):1111-5. ">Küpeli 2004</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>). </p> </section> <section id="CD013393-sec-0072"> <h6 class="title">Auxiliary treatments</h6> <p>This was an investigator assessed outcome not requiring judgment. Therefore, all 12 studies reporting this outcome were at low risk for detection bias (<a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a>; <a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a>; <a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>; <a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a>; <a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>). </p> </section> <section id="CD013393-sec-0073"> <h6 class="title">Major adverse events</h6> <p>This was an investigator assessed outcome that required judgment and, therefore, was viewed as an outcome for which blinding of outcome assessors was important. Based on the available information, four of seven studies were rated as high risk of bias (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>; <a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a>); one as unclear (<a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>) and two as low risk (<a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>). </p> </section> <section id="CD013393-sec-0074"> <h6 class="title">Quality of life</h6> <p>We found no trial reporting quality of life. </p> </section> <section id="CD013393-sec-0075"> <h6 class="title">Stone clearance time (continuous outcome)</h6> <p>This was an investigator assessed outcome that required judgment, and blinding of outcome assessors was therefore perceived as important. Two studies reported appropriate blinding (<a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>), in the three studies blinding status was unclear (<a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a>), whereas seven were unlikely to have blinded outcome assessors (<a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a>; <a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>; <a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a>; <a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a>).  </p> </section> </section> </section> <section id="CD013393-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed the risk of detection bias on a per outcome basis but since judgments were consistent across outcomes, we collapsed reporting into a single column. Two studies were at high risk of bias (for attrition levels of at least 20% in at least one treatment arm) (<a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>), 14 were at low risk of bias (with attrition levels less than 10% for both treatment arms) (<a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a>; <a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a>; <a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a>; <a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a>; <a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a>; <a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a>; <a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a>; <a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a>; <a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>; <a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a>; <a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>), whereas 20 were at unclear risk of bias (either because attrition rates could not be determined or ranged between 10% and less than 20%). </p> </section> <section id="CD013393-sec-0077"> <h4 class="title">Selective reporting</h4> <p>This bias was rated on a study level and reflected whether outcome reporting and analyses corresponded with an a priori protocol. We did not find any study protocols to compare; accordingly, all studies were at unclear risk for selective reporting bias. </p> </section> <section id="CD013393-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>Studies differed by the number of SWL sessions that were used, which we identified as potential source of bias. We sought to address this in a sensitivity analysis limited to studies in which participants clearly only underwent a single session (<a href="./references#CD013393-fig-0026" title="">Analysis 7.1</a>; <a href="./references#CD013393-fig-0027" title="">Analysis 7.2</a>; <a href="./references#CD013393-fig-0028" title="">Analysis 7.3</a>), which were only seven studies (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a>; <a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a>; <a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a>; <a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>; <a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a>). Ten studies used more than one session (<a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a>; <a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>; <a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a>; <a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a>; <a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a>; <a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a>; <a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a>; <a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a>; <a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>). The remainder were at unclear risk of bias since we could not determine the number if SWL sessions. </p> </section> </section> <section id="CD013393-sec-0079"> <h3 class="title" id="CD013393-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD013393-tbl-0001"><b>Summary of findings 1</b> Alpha‐blocker as adjuvant medical expulsive therapy plus usual care compared to usual care for renal and ureteral stones</a> </p> <section id="CD013393-sec-0080"> <h4 class="title">Alpha‐blockers as adjuvant medical expulsive therapy plus usual care compared to placebo and usual care or usual care alone </h4> <section id="CD013393-sec-0081"> <h5 class="title">Stone clearance</h5> <p>Alpha‐blockers may improve the clearance of stone fragments after SWL (RR 1.16, 95% CI 1.09 to 1.23; I² = 78%; studies = 36; participants = 4084; low certainty evidence; <a href="./references#CD013393-fig-0009" title="">Analysis 1.1</a>; <a href="#CD013393-fig-0003">Figure 3</a>). We downgraded the certainty of the evidence for study limitations (mainly due unclear allocation concealment, lack of blinding of participants and outcome assessors and unclear risk of selective reporting bias) and clinically important inconsistency (<a href="./full#CD013393-tbl-0001">summary of findings Table 1</a>). Funnel plot asymmetry contributed to the decision to downgrade by two levels overall (<a href="#CD013393-fig-0004">Figure 4</a>). Preplanned subgroup analyses identified no meaningful interactions to explain the observed inconsistency. </p> <div class="figure" id="CD013393-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot: alpha blocker and usual care versus usual care alone for stone clearance." data-id="CD013393-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot: alpha blocker and usual care versus usual care alone for stone clearance.</p> </div> </div> </div> <div class="figure" id="CD013393-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot: stone clearance." data-id="CD013393-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot: stone clearance.</p> </div> </div> </div> <p>Based on the stone clearance rate of 69.3% observed in the control arm, alpha‐blockers may increase stone clearance to 80.4%. This corresponds to 111 more (62 more to 159 more) per 1000 participants clearing their stone fragments after SWL with an alpha‐blocker versus usual care alone. </p> </section> <section id="CD013393-sec-0082"> <h5 class="title">Auxiliary treatment</h5> <p>Alpha‐blockers may reduce the need for auxiliary treatments after SWL (RR 0.67, 95% CI 0.45 to 1.00; I² = 16%; studies = 12; participants = 1251; low certainty evidence; <a href="./references#CD013393-fig-0010" title="">Analysis 1.2</a>; <a href="#CD013393-fig-0005">Figure 5</a>), but also includes the possibility of no effect. We downgraded the certainty of the evidence for study limitations (mainly due unclear allocation concealment, lack of blinding of participants and unclear risk of selective reporting bias) and clinically important imprecision given that the 95% CI of the absolute effect size estimate crossed an assumed 3% threshold of clinical importance (and included the possibility of no effect) (<a href="./full#CD013393-tbl-0001">summary of findings Table 1</a>). Funnel plot asymmetry contributed to the decision to downgrade by two levels overall (<a href="#CD013393-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD013393-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot: alpha blocker and usual care versus usual care alone for auxiliary treatment." data-id="CD013393-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot: alpha blocker and usual care versus usual care alone for auxiliary treatment.</p> </div> </div> </div> <div class="figure" id="CD013393-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot: auxiliary treatment." data-id="CD013393-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot: auxiliary treatment.</p> </div> </div> </div> <p>Based on a rate of auxiliary treatments in the usual care arm of 9.7%, alpha‐blockers may reduce the rate to 6.5%. This corresponds to 32 fewer (53 fewer to 0 fewer) per 1000 participants undergoing auxiliary treatments. This analysis did not consider additional SWL sessions as a form of auxiliary treatment (although several trials reported its use in this way, i.e. <a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a>; and <a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a>).  </p> </section> <section id="CD013393-sec-0083"> <h5 class="title">Major adverse events</h5> <p>Alpha‐blockers may reduce major adverse events (RR 0.60, 95% CI 0.46 to 0.80; I² = 0%; studies = 7; participants = 747; low certainty evidence; <a href="./references#CD013393-fig-0011" title="">Analysis 1.3</a>; <a href="#CD013393-fig-0007">Figure 7</a>); this corresponds to 106 fewer (144 fewer to 53 fewer) major adverse events per 1000. We downgraded the certainty of the evidence twice for study limitations mainly due to unclear allocation concealment, lack of blinding of participants and outcome assessors, and concerns about selective reporting bias in some studies (all without protocols) addressing this outcome (<a href="./full#CD013393-tbl-0001">summary of findings Table 1</a>). There were too few studies to assess for funnel plot asymmetry. </p> <div class="figure" id="CD013393-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot: alpha blocker and usual care versus usual care alone for major adverse events." data-id="CD013393-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot: alpha blocker and usual care versus usual care alone for major adverse events. </p> </div> </div> </div> <p>Major adverse events occurred in 25.8% of participants in the usual care group; alpha‐blockers would reduce this to 15.5%. This corresponds to 103 fewer (139 fewer to 52 fewer) major adverse events per 1000 with alpha‐blocker treatment compared to usual care alone. </p> <p><a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a> reported much higher rates of major adverse events than any other study for both treatments arms. Removing this study resulted in a lower control event of 13.8%. Using this as control event rate, the observed relative effect size would result in 55 fewer (75 fewer to 28 fewer) major adverse events per 1000 participants compared to usual care. </p> <p>None of the reported major adverse events were reported to be related to the alpha‐blocker such as syncope or hypotension. Unplanned emergency room visits and rehospitalization for stone related issues were the main contributors. </p> </section> <section id="CD013393-sec-0084"> <h5 class="title">Quality of life</h5> <p>No study reported quality of life. </p> </section> <section id="CD013393-sec-0085"> <h5 class="title">Stone clearance time</h5> <p>Alpha‐blockers may reduce the time for stone clearance (MD –3.74, 95% CI –5.25 to –2.23; I² = 86%; studies = 14; participants = 1790; low certainty evidence; <a href="./references#CD013393-fig-0012" title="">Analysis 1.4</a>). We downgraded the certainty of the evidence for study limitations (mainly due unclear allocation concealment, lack of blinding of participants and outcome assessors, and unclear risk of selective reporting bias) and concerns over publication bias given the asymmetric funnel plot (<a href="#CD013393-fig-0008">Figure 8</a>). We did not downgrade for inconsistency despite the high I² statistic since this (and the observed imprecision) did not appear clinically relevant to its interpretation. </p> <div class="figure" id="CD013393-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot: stone clearance time." data-id="CD013393-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot: stone clearance time.</p> </div> </div> </div> <p>The time to stone clearance varied very considerably between studies with a range from 3.6 days to 47.2 days. </p> </section> </section> <section id="CD013393-sec-0086"> <h4 class="title">Predefined subgroup analysis by stone location (renal and proximal ureter versus distal ureter) </h4> <section id="CD013393-sec-0087"> <h5 class="title">Stone clearance</h5> <p>The test for subgroup differences did not meet statistical significance (P = 0.10; <a href="./references#CD013393-fig-0013" title="">Analysis 2.1</a>). Differences between results for participants with renal and proximal ureteral stones (RR 1.15, 95% CI 1.06 to 1.25; I² = 72%; studies = 19; participants = 1947) and those with distal ureteral stones (RR 1.40, 95% CI 1.13 to 1.74; I² = 71%; studies = 6; participants = 699) may be attributable to chance. </p> </section> <section id="CD013393-sec-0088"> <h5 class="title">Auxiliary treatment </h5> <p>The test for subgroup differences did not meet statistical significance (P = 0.51; <a href="./references#CD013393-fig-0014" title="">Analysis 2.2</a>). Differences between results between participants with renal and proximal ureteral stones (RR 0.62, 95% CI 0.40 to 0.98; I² = 4%; studies = 11; participants = 1121) and those with distal ureteral stones (RR 1.00, 95% CI 0.26 to 3.83; studies = 1; participants = 130) may be attributable to chance. </p> </section> <section id="CD013393-sec-0089"> <h5 class="title">Major adverse events</h5> <p>The test for subgroup differences did not meet statistical significance (P = 0.45; <a href="./references#CD013393-fig-0015" title="">Analysis 2.3</a>). Differences between results for participants with renal and proximal ureteral stones (RR 0.59, 95% CI 0.44 to 0.79; I² = 0%; studies = 6; participants = 617) and those with distal ureteral stones (RR 1.00, 95% CI 0.26 to 3.83; studies = 1; participants = 130) may be attributable to chance. </p> </section> </section> <section id="CD013393-sec-0090"> <h4 class="title"><i>Post hoc</i> subgroup analysis by stone location (renal versus ureteral) </h4> <section id="CD013393-sec-0091"> <h5 class="title">Stone clearance</h5> <p>The test for subgroup differences did not meet statistical significance (P = 0.09; <a href="./references#CD013393-fig-0016" title="">Analysis 3.1</a>). Differences between results for participants with renal stones (RR 1.13, 95% CI 1.03 to 1.24; I² = 73%; studies = 12; participants = 1483) and those with ureteral stones (RR 1.31, 95% CI 1.14 to 1.51; I² = 69%; studies = 13; participants = 1163) may be attributable to chance. </p> </section> <section id="CD013393-sec-0092"> <h5 class="title">Auxiliary treatment </h5> <p>The test for subgroup differences did not meet statistical significance (P = 0.44; <a href="./references#CD013393-fig-0017" title="">Analysis 3.2</a>). Differences between results between participants with renal stones (RR 0.52, 95% CI 0.25 to 1.08; I² = 4%; studies = 8; participants = 922) and those with ureteral stones (RR 0.74, 95% CI 0.44 to 1.25; I² = 0%; studies = 4; participants = 329) may be attributable to chance. </p> </section> <section id="CD013393-sec-0093"> <h5 class="title">Major adverse events</h5> <p>The test for subgroup differences did not meet statistical significance (P = 0.45; <a href="./references#CD013393-fig-0018" title="">Analysis 3.3</a>). Differences between results for participants with renal and proximal ureteral stones (RR 0.59, 95% CI 0.44 to 0.79; I² = 0%; studies = 6; participants = 617) and those with distal ureteral stones (RR 1.00, 95% CI 0.26 to 3.83; studies = 1; participants = 130) may be attributable to chance. </p> </section> </section> <section id="CD013393-sec-0094"> <h4 class="title">Predefined subgroup analysis by stone size (less than 10 mm versus 10 mm or greater)</h4> <section id="CD013393-sec-0095"> <h5 class="title">Stone clearance</h5> <p>The test for subgroup differences did not meet statistical significance (P = 0.08; <a href="./references#CD013393-fig-0019" title="">Analysis 4.1</a>). Differences between results for participants with stones less than 1 cm in size (RR 1.03, 95% CI 0.96 to 1.11; I² = 0%; studies = 7; participants = 411) and those with stones 1 cm or greater in size (RR 1.24, 95% CI 1.02 to 1.50; I² = 44%; studies = 6; participants = 369) may be attributable to chance. </p> </section> <section id="CD013393-sec-0096"> <h5 class="title">Auxiliary treatment</h5> <p>We found no data to perform this subgroup analysis on auxiliary treatment.</p> </section> <section id="CD013393-sec-0097"> <h5 class="title">Major adverse events</h5> <p>We found no data to perform this subgroup analysis on major adverse events.</p> </section> </section> <section id="CD013393-sec-0098"> <h4 class="title">Predefined subgroup analysis by specific alpha‐blocker</h4> <section id="CD013393-sec-0099"> <h5 class="title">Stone clearance</h5> <p>The test for subgroup differences was not significant (P = 0.75; <a href="./references#CD013393-fig-0020" title="">Analysis 5.1</a>). Results for participants receiving a different type of alpha‐blocker ranged from RR 1.02 for silodosin (95% CI 0.46 to 2.26; I² = 9%; studies = 2; participants = 54), RR 1.12 for alfuzosin (95% CI 0.89 to 1.40; I² = 68%; studies = 3; participants = 254), RR 1.17 for tamsulosin (95% CI 1.09 to 1.25; I² = 81%; studies = 31; participants = 3465), to RR 3.37 for naftopidil (95% CI 0.50 to 22.69; studies = 1; participants = 27). The differences may be attributable to chance variation.  </p> </section> <section id="CD013393-sec-0100"> <h5 class="title">Auxiliary treatment</h5> <p>The test for subgroup differences was not significant (P = 0.41; <a href="./references#CD013393-fig-0021" title="">Analysis 5.2</a>). Of 12 included studies, 10 used tamsulosin, one used doxazosin (<a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a>) and one used silodosin (<a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>).  </p> </section> <section id="CD013393-sec-0101"> <h5 class="title">Major adverse events</h5> <p>The test for subgroup differences was not significant (P = 0.50; <a href="./references#CD013393-fig-0022" title="">Analysis 5.3</a>). Of seven included studies, six used use tamsulosin, and one used silodosin (<a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>).  </p> </section> </section> <section id="CD013393-sec-0102"> <h4 class="title">Predefined subgroup analysis by type of lithotripter (HM3 versus others)</h4> <p>We were unable to conduct this preplanned subgroup analysis as none of the studies used an HM3 lithotripter. </p> </section> <section id="CD013393-sec-0103"> <h4 class="title">Sensitivity analyses limited to low risk of bias studies</h4> <section id="CD013393-sec-0104"> <h5 class="title">Stone clearance</h5> <p>When limited to studies in which outcome assessors were blinded (<a href="./references#CD013393-bbs2-0023" title="KüpeliB , IrkilataL , GürocakS , TunçL , KiraçM , KaraoglanU , et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?Urology2004;64(6):1111-5. ">Küpeli 2004</a>; <a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>), alpha‐blockers may improve the clearance of stone fragments after SWL (RR 1.52, 95% CI 0.86 to 2.68; I² = 83%; studies = 3; participants = 237; <a href="./references#CD013393-fig-0023" title="">Analysis 6.1</a>), which were broadly similar to the results of the overall analysis (RR 1.16, 95% CI 1.09 to 1.23; I² = 78%; studies = 36; participants = 4084; <a href="./references#CD013393-fig-0009" title="">Analysis 1.1</a>). </p> </section> <section id="CD013393-sec-0105"> <h5 class="title">Auxiliary treatment</h5> <p>Blinding of outcome assessors was not relevant to this outcome. When limited to studies in which participants were blinded and this outcome was reported (<a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a>; <a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a>; <a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>), alpha‐blockers may reduce the need for auxiliary treatments after SWL (RR 0.18, 95% CI 0.03 to 1.00; I² = 0%; studies = 3; participants = 260; <a href="./references#CD013393-fig-0024" title="">Analysis 6.2</a>), which were similar to the results of the overall analysis (RR 0.67, 95% CI 0.45 to 1.00; I² = 0%; studies = 12; participants = 1251; <a href="./references#CD013393-fig-0010" title="">Analysis 1.2</a>). </p> </section> <section id="CD013393-sec-0106"> <h5 class="title">Major adverse events</h5> <p>When limited to the single study in which outcome assessors were blinded and this outcome was reported (<a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a>), alpha‐blockers may not effect major adverse events (RR 1.0, 95% CI 0.32 to 3.17; studies = 1; participants = 76; <a href="./references#CD013393-fig-0025" title="">Analysis 6.3</a>), in contrast to the results of overall analysis (RR 0.60, 95% CI 0.46 to 0.80; I² = 0%; studies = 7; participants = 747; <a href="./references#CD013393-fig-0011" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD013393-sec-0107"> <h4 class="title">Sensitivity analyses limited to studies with a single shock wave lithotripsy session</h4> <section id="CD013393-sec-0108"> <h5 class="title">Stone clearance</h5> <p>When limited to studies that used a single SWL session (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>; <a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a>; <a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a>; <a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a>; <a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a>; <a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a>), alpha‐blockers may increase stone clearance (RR 1.22, 95% CI 1.04 to 1.42; I² = 71%; studies = 7; participants = 993; <a href="./references#CD013393-fig-0026" title="">Analysis 7.1</a>), similar to the results of the overall analysis (RR 1.16, 95% CI 1.09 to 1.23; I² = 78%; studies = 36; participants = 4084; <a href="./references#CD013393-fig-0009" title="">Analysis 1.1</a>). </p> </section> <section id="CD013393-sec-0109"> <h5 class="title">Auxiliary treatment</h5> <p>When limited to studies that employed a single SWL session (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>), alpha‐blockers may reduce auxiliary treatments after SWL (RR 0.81, 95% CI 0.54 to 1.23; I² = 25%; studies = 2; participants = 309; <a href="./references#CD013393-fig-0027" title="">Analysis 7.2</a>), similar to the results of the overall analysis (RR 0.67, 95% CI 0.46 to 0.80; participants = 1251; studies = 12; I² = 0%; <a href="./references#CD013393-fig-0010" title="">Analysis 1.2</a>). </p> </section> <section id="CD013393-sec-0110"> <h5 class="title">Major adverse events</h5> <p>When limited to studies that employed a single SWL session (<a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>; <a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a>), alpha‐blockers may reduce major adverse events (RR 0.62, 95% CI 0.45 to 0.85; I² = 0%; studies = 2; participants = 309; <a href="./references#CD013393-fig-0028" title="">Analysis 7.3</a>), similar to the results of the overall analysis (RR 0.60, 95% CI 0.46 to 0.80; I² = 0%; studies = 7; participants = 747; <a href="./references#CD013393-fig-0011" title="">Analysis 1.3</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013393-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013393-sec-0111"></div> <section id="CD013393-sec-0112"> <h3 class="title" id="CD013393-sec-0112">Summary of main results</h3> <p>Based on the findings of this systematic review, alpha‐blockers may improve stone clearance, reduce the need for auxiliary treatments and reduce major adverse events. We found no evidence to suggest that stone clearance might differ by stone location (renal and proximal ureter versus distal ureter) or stone size (less than 1 cm versus 1 cm or greater). Stone clearance does not appear to vary by type of alpha‐blocker. We were unable to perform subgroup analyses for the outcomes of auxiliary treatments and major adverse events. We were unable to compare results by type of lithotripter. Results of sensitivity analyses limited to studies in which participants were blinded and those in which participants clearly received only one SWL session did not substantially differ from the main analysis for any of the three primary outcomes of this review. </p> </section> <section id="CD013393-sec-0113"> <h3 class="title" id="CD013393-sec-0113">Overall completeness and applicability of evidence</h3> <p>This systematic review included 40 RCTs from a variety of different geographic areas enrolling participants with stones of different locations, stone sizes and using different types of alpha‐blockers. The shock wave lithotripter participants were treated with the most commonly used device currently found in clinical practice. Therefore, results of this review appear largely applicable to people with renal or ureteral stones for the outcomes for which we could find relevant evidence. </p> <p>We included the outcome of major adverse events to capture potential drug‐related adverse effects such as episodes of syncope or symptomatic hypotension but found none. This was unexpected given that this review accounts for an aggregate number of over 2000 participants receiving an alpha‐blocker. Based on a subgroup analysis of higher quality studies in a Cochrane Review on the role of alpha‐blockers as MET in ureteral colic (<a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a>), we expected to find approximately three more major adverse events per 1000 as drug‐related adverse effects. Failure to find any such events may relate to the mostly poor study quality of trials included in this review, which did not systematically query participants for drug‐related adverse events.  </p> <p>We would also like to emphasize that the outcome of time to stone clearance should not be misinterpreted as a time‐to‐event outcome. Instead, it is a continuous outcome that reflects the time to stone clearance of those participants that passed their stone fragments.  </p> <p>The decision by guideline panels whether to recommend alpha‐blockers after SWL or not likely hinges on the perceived trade‐off of desirable and undesirable effects of this drug class. This review would suggest that the rate of major adverse events favor the use of alpha‐blockers whereas minor adverse events were not captured. The findings of <a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a> with regard to the adverse effect profile of this drug class as primary treatment for ureteral colic would suggest the treatment burden to be low. Current AUA guidelines make a 'moderate recommendation' for the use of alpha‐blockers after SWL (<a href="./references#CD013393-bbs2-0069" title="AssimosD , KrambeckA , MillerNL , MongaM , MuradMH , NelsonCP , et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part I. Journal of Urology2016;196(4):1153-60. [PMID: 27238616]">Assimos 2016a</a>). The EAU guidelines stating that alpha‐blockers after SWL for ureteral or renal stones may expedite expulsion, increase stone free rates and reduce analgesic requirements mention alpha‐blockers but fail to make an explicit recommendation (<a href="./references#CD013393-bbs2-0144" title="TurkC , NeisiusA , PetrikA , SeitzC , SkolarikosA . EAU urolithiasis guidelines, 2020. uroweb.org/guideline/urolithiasis (accessed prior to 19 August 2020).">Turk 2020</a>). National Institute for Health and Care Excellence (NICE) guidelines indicate that clinicians should consider adjunctive therapy for adults having SWL for ureteral stones less than 10 mm (<a href="./references#CD013393-bbs2-0118" title="National Institute for Health and Care Excellence. NICE guideline – renal and ureteric stones: assessment and management. BJU International2019;123(2):220-32.">NICE 2019</a>). </p> </section> <section id="CD013393-sec-0114"> <h3 class="title" id="CD013393-sec-0114">Quality of the evidence</h3> <p>Findings of this review are based on a large number of relatively small trials that lacked published protocols, were not transparently reported and had important methodological limitations. None of the included trials had a registered protocol, which is noteworthy and very concerning. Therefore, we consistently downgraded the certainty of evidence (assessed on a per outcome basis) for several issues. Allocation concealment was frequently unclear, and participants and outcome assessors were commonly not blinded. In addition, loss to follow‐up rates were often unclear and the number participants who received more than one SWL session and the number of such sessions was unclear. </p> <p>In addition, several analyses were marked by high degrees of unexplained, clinically relevant inconsistency, highly suspected publication bias, or a combination of these. Finally, CIs around pooled effect size estimates for the outcomes of auxiliary treatment and major adverse events were often wide, which prompted us to downgrade the certainty of evidence further for some outcomes. </p> </section> <section id="CD013393-sec-0115"> <h3 class="title" id="CD013393-sec-0115">Potential biases in the review process</h3> <p>All aspects of this review were governed by an a priori protocol and conducted based on rigorous Cochrane guidance. However, a few aspects could have potentially introduced bias beyond the issues already described. </p> <p> <ul id="CD013393-list-0024"> <li> <p>Although we conducted a comprehensive literature search of multiple electronic databases of published and unpublished studies as well as trial registries, it is possible that some studies were missed, in particular small, negative studies in non‐English languages. Failure to include such studies (if they exist) would have biased studies results towards a larger effect size. Concern over publication bias prompted us to lower our confidence in the estimates of effect for the need for auxiliary treatment and major adverse events. It may also be helpful to note that at least six studies in the <a href="#CD013393-sec-0063">Excluded studies</a> section were aborted for unclear reasons, which have been due to negative findings. </p> </li> <li> <p>We were unable to fully assess eligibility of a study originating from China, for which we could not find a qualified translator. Its results are included based on the English language abstract. We also contacted study authors for additional methodological or clinical data but rarely received informative responses. </p> </li> <li> <p>We revised our threshold for a clinically important effect size for auxiliary treatments from originally 5% in the protocol (<a href="./references#CD013393-bbs2-0153" title="OestreichMC , SathianathenNJ , HwangEC , VernooijRW , KuntzGM , ScalesCD , et al. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD013393. [DOI: 10.1002/14651858.CD013393]">Oestreich 2019</a>) to 3% after realizing that relatively small differences in rates likely resulted in large perceived disutilities by patients. We fully acknowledge that different thresholds may lead to different interpretations and would like to emphasize the importance of transparency (<a href="./references#CD013393-bbs2-0100" title="HultcrantzM , RindD , AklEA , TreweekS , MustafaRA , IorioA , et al. The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology2017;87:4-13.">Hultcrantz 2017</a>). </p> </li> <li> <p>Results of this study were limited to RCTs in accordance with the published protocol. This was motivated not only by Cochrane guidance, but also prior knowledge of a large body of RCTs based on published systematic reviews. Although it is possible that evidence from well‐designed non‐RCTs may have provided higher quality evidence for select outcomes, this appears unlikely. </p> </li> </ul> </p> </section> <section id="CD013393-sec-0116"> <h3 class="title" id="CD013393-sec-0116">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic reviews have been performed to address the same clinical question, which will be reviewed in chronological order. </p> <p> <ul id="CD013393-list-0025"> <li> <p><a href="./references#CD013393-bbs2-0112" title="LosekRL , MauroLS . Efficacy of tamsulosin with extracorporeal shock wave lithotripsy for passage of renal and ureteral calculi. Annals of Pharmacotherapy2008;42(5):692-7.">Losek 2008</a> reported a narrative review focused on tamsulosin. It included, but did not pool, five trials. The certainty of evidence was not assessed. It found that tamsulosin may promote the passage of renal stones after SWL but that for ureteral stones was inconclusive. </p> </li> <li> <p><a href="./references#CD013393-bbs2-0134" title="SchulerTD , ShahaniR , HoneyRJ , PaceKT . Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: a systematic review and meta-analysis. Journal of Endourology2009;23(3):387-93.">Schuler 2009</a> identified four trials of different adjunctive agents (including two trials of tamsulosin). It did not assess the certainty of evidence. Its findings suggested improved stone clearance with MET, in particular for stones greater than 10 mm. </p> </li> <li> <p>In the most rigorous and comprehensive systematic review to date of primary MET and after SWL that included both alpha‐blockers and calcium channel blockers. <a href="./references#CD013393-bbs2-0136" title="SeitzC , LiatsikosE , PorpigliaF , TiseliusHG , ZwergelU . Medical therapy to facilitate the passage of stones: what is the evidence?European Urology2009;56(3):455-71.">Seitz 2009</a> found an RR of stone clearance of 1.29 (95% CI 1.16 to 1.43) with alpha‐blocker use based on 13 trials with 1007 participants. It assessed study quality using the Jadad scale, which is no longer considered appropriate today but the certainty of evidence was otherwise not qualified. </p> </li> <li> <p><a href="./references#CD013393-bbs2-0151" title="ZhengS , LiuLR , YuanHC , WeiQ . Tamsulosin as adjunctive treatment after shockwave lithotripsy in patients with upper urinary tract stones: a systematic review and meta-analysis. Scandinavian Journal of Urology and Nephrology2010;44(6):425-32.">Zheng 2010</a> reported a systematic review focused on tamsulosin and the upper urinary tract. It assessed study quality using the Jadad scale but did not provide the certainty of the evidence. Stone clearance was similarly improved. </p> </li> <li> <p><a href="./references#CD013393-bbs2-0152" title="ZhuY , DuijveszD , RoversMM , LockTM . Alpha-blockers to assist stone clearance after extracorporeal shock wave lithotripsy: a meta-analysis. BJU International2010;106(2):256-61.">Zhu 2010</a> considered all alpha‐blockers but only included seven trials excluding those with unclear methods and those that included spasmolytics. They reported an absolute risk difference favoring alpha‐blockers of 16% (95% CI 5% to 27%). Based on an assessment using the Cochrane 'Risk of bias' tool, it found the methodological quality of the included studies to be adequate. </p> </li> <li> <p><a href="./references#CD013393-bbs2-0109" title="LeeJK , JeongCW , JeongSJ , HongSK , ByunSS , LeeSE . Impact of tamsulosin on ureter stone expulsion in Korean patients: a meta-analysis of randomized controlled studies. Korean Journal of Urology2012;53(10):699-704.">Lee 2012</a> focused on the role of tamsulosin as MET both as primary adjuvant treatment and after SWL (as did <a href="./references#CD013393-bbs2-0136" title="SeitzC , LiatsikosE , PorpigliaF , TiseliusHG , ZwergelU . Medical therapy to facilitate the passage of stones: what is the evidence?European Urology2009;56(3):455-71.">Seitz 2009</a>), but limited to Korean patients only. It used the Jadad scale and did not provide the certainty of the evidence rating. The results favored the use of tamsulosin over no MET. </p> </li> <li> <p><a href="./references#CD013393-bbs2-0110" title="LiM , WangZ , YangJ , GuoX , WangT , WangS , et al. Adjunctive medical therapy with alpha-blocker after extracorporeal shock wave lithotripsy of renal and ureteral stones: a meta-analysis. PloS One2015;10(4):e0122497.">Li 2015</a> included 23 trials for any alpha‐blocker. It used the Jadad scale and did not rate the certainty of evidence. Alpha‐blockers improved stone clearance and reduced pain. Dizziness, anejaculation and headache were increased. </p> </li> <li> <p><a href="./references#CD013393-bbs2-0141" title="SkolarikosA , GrivasN , KallidonisP , MourmourisP , RountosT , FiamegosA , et al. The efficacy of medical expulsive therapy (MET) in improving stone-free rate and stone expulsion time, after extracorporeal shock wave lithotripsy (SWL) for upper urinary stones: a systematic review and meta-analysis. Urology2015;86(6):1057-64.">Skolarikos 2015</a> included calcium channel blockers, alpha‐blockers and other adjuvant agents. The authors did not report any assessment of study quality. They found improved stone expulsion rates with alpha‐blockers, which appeared independent of the type of alpha‐blocker, the stone diameter or the stone location. </p> </li> <li> <p><a href="./references#CD013393-bbs2-0148" title="YangTX , LiaoBH , ChenYT , LiH , HeQ , LiuQY , et al. A network meta-analysis on the beneficial effect of medical expulsive therapy after extracorporeal shock wave lithotripsy. Scientific Reports2017;7(1):14429.">Yang 2017</a> reported the latest systematic review that included a meta‐analysis but did not characterize the quality of evidence on a per outcome basis. The findings of the network meta‐analysis supported a positive impact of alpha‐blockers over no adjuvant therapy and favored doxazosin over tamsulosin over terazosin. In contrast, subgroup analyses conducted in this review were not suggestive of any interaction of the effect on stone clearance and the type of alpha‐blockers. </p> </li> </ul> </p> <p>In summary, a large number of existing systematic reviews support a positive effect of alpha‐blockers on stone clearance as well as other outcomes. What distinguishes our review from prior reviews was the certainty of evidence rating on a per outcomes basis. The certainty of evidence was low for all three primary outcomes of this review, which means that our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. This qualifier appears relevant in the context of the ongoing controversy about the effect of alpha‐blockers also as part of the primary management approach for ureteral colic (<a href="./references#CD013393-bbs2-0073" title="CampschroerT , ZhuX , VernooijRW , LockMT . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD008509. [DOI: 10.1002/14651858.CD008509.pub3]">Campschroer 2018</a>). Whereas some doubt their value (<a href="./references#CD013393-bbs2-0079" title="De ConinckV , AntonelliJ , ChewB , PattersonJM , SkolarikosA , BultitudeM . Medical expulsive therapy for urinary stones: future trends and knowledge gaps. European Urology2019;76(5):658-66.">De Coninck 2019</a>), others see its main benefit in people with larger ureteral stones of 5 mm or greater in size (<a href="./references#CD013393-bbs2-0078" title="DahmP , HollingsworthJM . Medical expulsive therapy for ureteral stones – stone age medicine. JAMA Internal Medicine2018;178(8):1058-9.">Dahm 2018</a>; <a href="./references#CD013393-bbs2-0098" title="HollingsworthJM , CanalesBK , RogersMA , SukumarS , YanP , KuntzGM , et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ (Clinical Research Ed.)2016;355:i6112. [PMID: 27908918]">Hollingsworth 2016</a>). These systematic reviews included several large randomized trials of much higher methodological rigor than any of the studies included here. Stone fragments resulting from SWL should be in the 1 mm to 3 mm size range; if these were primary ureteral stones and the result from systematic reviews of primary MET for ureteral colic were directly applicable, the benefit would be questionable. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013393-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013393-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD013393-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot: alpha blocker and usual care versus usual care alone for stone clearance." data-id="CD013393-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot: alpha blocker and usual care versus usual care alone for stone clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot: stone clearance." data-id="CD013393-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot: stone clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot: alpha blocker and usual care versus usual care alone for auxiliary treatment." data-id="CD013393-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot: alpha blocker and usual care versus usual care alone for auxiliary treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot: auxiliary treatment." data-id="CD013393-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot: auxiliary treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot: alpha blocker and usual care versus usual care alone for major adverse events." data-id="CD013393-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot: alpha blocker and usual care versus usual care alone for major adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Funnel plot: stone clearance time." data-id="CD013393-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot: stone clearance time.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blocker and usual care versus usual care alone, Outcome 1: Stone clearance" data-id="CD013393-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blocker and usual care versus usual care alone, Outcome 1: Stone clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blocker and usual care versus usual care alone, Outcome 2: Auxiliary treatment" data-id="CD013393-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blocker and usual care versus usual care alone, Outcome 2: Auxiliary treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blocker and usual care versus usual care alone, Outcome 3: Major adverse events" data-id="CD013393-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blocker and usual care versus usual care alone, Outcome 3: Major adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blocker and usual care versus usual care alone, Outcome 4: Stone clearance time" data-id="CD013393-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blocker and usual care versus usual care alone, Outcome 4: Stone clearance time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal and proximal ureter versus distal ureter), Outcome 1: Stone clearance" data-id="CD013393-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal and proximal ureter versus distal ureter), Outcome 1: Stone clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal and proximal ureter versus distal ureter), Outcome 2: Auxiliary treatment" data-id="CD013393-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal and proximal ureter versus distal ureter), Outcome 2: Auxiliary treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal and proximal ureter versus distal ureter), Outcome 3: Major adverse events" data-id="CD013393-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal and proximal ureter versus distal ureter), Outcome 3: Major adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal versus ureter; post hoc), Outcome 1: Stone clearance" data-id="CD013393-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal versus ureter; post hoc), Outcome 1: Stone clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal versus ureter; post hoc), Outcome 2: Auxiliary treatment" data-id="CD013393-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal versus ureter; post hoc), Outcome 2: Auxiliary treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal versus ureter; post hoc), Outcome 3: Major adverse events" data-id="CD013393-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Alpha‐blocker and usual care versus usual care: stone location subgroup (renal versus ureter; post hoc), Outcome 3: Major adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Alpha‐blocker and usual care versus usual care: stone size subgroup, Outcome 1: Stone clearance" data-id="CD013393-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Alpha‐blocker and usual care versus usual care: stone size subgroup, Outcome 1: Stone clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup, Outcome 1: Stone clearance" data-id="CD013393-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup, Outcome 1: Stone clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup, Outcome 2: Auxiliary treatment" data-id="CD013393-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup, Outcome 2: Auxiliary treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup, Outcome 3: Major adverse events" data-id="CD013393-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup, Outcome 3: Major adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Alpha‐blockers and usual care versus usual care: risk of bias (sensitivity analysis), Outcome 1: Stone clearance" data-id="CD013393-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Alpha‐blockers and usual care versus usual care: risk of bias (sensitivity analysis), Outcome 1: Stone clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Alpha‐blockers and usual care versus usual care: risk of bias (sensitivity analysis), Outcome 2: Auxiliary treatment" data-id="CD013393-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Alpha‐blockers and usual care versus usual care: risk of bias (sensitivity analysis), Outcome 2: Auxiliary treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Alpha‐blockers and usual care versus usual care: risk of bias (sensitivity analysis), Outcome 3: Major adverse events" data-id="CD013393-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Alpha‐blockers and usual care versus usual care: risk of bias (sensitivity analysis), Outcome 3: Major adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Alpha‐blocker and usual care versus usual care: single SWL session (sensitivity analysis), Outcome 1: Stone clearance" data-id="CD013393-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Alpha‐blocker and usual care versus usual care: single SWL session (sensitivity analysis), Outcome 1: Stone clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Alpha‐blocker and usual care versus usual care: single SWL session (sensitivity analysis), Outcome 2: Auxiliary treatment" data-id="CD013393-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Alpha‐blocker and usual care versus usual care: single SWL session (sensitivity analysis), Outcome 2: Auxiliary treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013393-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/urn:x-wiley:14651858:media:CD013393:CD013393-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Alpha‐blocker and usual care versus usual care: single SWL session (sensitivity analysis), Outcome 3: Major adverse events" data-id="CD013393-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_t/tCD013393-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Alpha‐blocker and usual care versus usual care: single SWL session (sensitivity analysis), Outcome 3: Major adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/media/CDSR/CD013393/image_n/nCD013393-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013393-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Alpha‐blocker as adjuvant medical expulsive therapy plus usual care compared to usual care for renal and ureteral stones</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Alpha‐blocker and usual care compared to usual care for renal and ureteral stones</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with renal and ureteral stones undergoing shock wave lithotripsy<br/><b>Setting:</b> outpatient or inpatient<br/><b>Intervention:</b> alpha‐blocker and usual care<br/><b>Comparison:</b> usual care </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Effect size<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard care</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with alpha‐blocker</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stone clearance</b> </p> <p>assessed by imaging</p> <p>Follow‐up range: 1 week to 3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4084<br/>(36 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b><br/>(1.09 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Moderate risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>693 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 more per 1000<br/>(62 more to 159 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Auxiliary treatment</b> </p> <p>Follow‐up range: 1 week to 3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1251<br/>(12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.67</b> </p> <p>(0.45 to 1.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Moderate risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 fewer per 1000</p> <p>(53 fewer to 0 fewer)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Major adverse events</b> </p> <p>determined by study investigators</p> <p>Follow‐up range: 1 week to 3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>747<br/>(7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.60</b><br/>(0.46 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Moderate risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 fewer per 1000<br/>(139 fewer to 52 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b><sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 fewer per 1000</p> <p>(139 fewer to 34 fewer)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stone clearance time</b> </p> <p>measured in days </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1790<br/>(14 studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,g,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Moderate risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 3.61–47.2 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.74 fewer days</p> <p>(5.25 fewer to 2.23 fewer days)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>N/A:</b> not applicable; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for unclear risk of selection bias, high risk of performance and detection bias, and unclear risk of selective reporting bias.<br/><sup>b</sup>Downgraded one level due to clinically important, unexplained inconsistency with high I² value.<br/><sup>c</sup>Concerns over possible publication bias given funnel plot asymmetry contributed to decision to downgraded by two levels overall.<br/><sup>d</sup>Imprecision with wide confidence intervals around absolute effect size estimates that crossed the threshold of 3% clinically relevant absolute risk reduction.<br/><sup>e</sup>Downgraded two levels for unclear risk of selection bias, high risk of performance and detection bias, and high risk of selective reporting bias for this infrequently reported outcome.<br/><sup>f</sup>Lower, presumably more representative control event rate of 17% obtained by excluding <a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a>.<br/><sup>g</sup>Downgraded one level given funnel plot asymmetry and serious risk of publication bias.<br/><sup>h</sup>We noted a high degree of inconsistency but did not downgrade given its perceived lack of clinical importance. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Alpha‐blocker as adjuvant medical expulsive therapy plus usual care compared to usual care for renal and ureteral stones</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013393-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial period (year to year)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Setting/country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SWL description (lithotripter; number shocks; power setting)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number SWL sessions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Stone location (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Largest stone size (mm, mean ± SD)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single upper ureteric stone &lt; 15 mm in size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Lithostar Multiline; max 3500 shocks; 14.4–15.1 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 ± 1.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (NSAIDs, antispasmodics, or tramadol PRN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 ± 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2013–2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Saudi Arabia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Solitary renal stone &lt; 20 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Dornier SII; max 3500 shocks; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.06 ± 3.82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac potassium 50 mg BID for 2 days, additional doses PRN; drink plenty of fluids) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.56 ± 3.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009–2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal colic and upper ureteral stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Siemens Lithoscope; max 3000 shocks; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin 4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.06 ± 1.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium PRN; drink fluid to provide urine output ≥ 2 L/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 ± 2.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal calculi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin 10 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (standard analgesia PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004–2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single radiopaque renal 6–24 mm or ureteral 6–15 mm calculus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dornier Compact S Lithotripter; 1,500 shocks; 14–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 calyx/6 pelvis/5 upper renal/4 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (proxyvon [65 mg dextropropoxyphene hydrochloride and 400 mg acetaminophen] daily PRN; minimum 2.5 L fluids) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 calyx/9 pelvis/6 upper renal/2 lower ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008–2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Solitary 6–15 mm ureteral stone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Storz Medical AG Modulith Slk; 2700–3600 shocks; 6–19 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.4 ± 3.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 75 mg IM PRN, pantoprazole 40 mg/day, after discharge drink 2 L water daily) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7 ± 3.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal stones undergoing ESWL up to 3 times</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (analgesic not further defined)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with radio‐opaque ureter stones 5–10 mm in diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comed Lithotripsy SDS‐5000; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin 10 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 upper ureteral/6 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 ± 1.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (loxoprofen sodium 68.1 mg PRN; 2 L fluids daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 upper ureteral/6 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 ± 1.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2012–2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Presumed single center/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single radiopaque renal stone (0.5–2 cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>EDAP integrated Sonolith 4000 plus; max 3500 shocks; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 upper renal/7 mid‐renal/5 lower renal/5 pelvis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.28 ± 2.46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care not further defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 upper renal/6 mid‐renal/2 lower renal/9 pelvis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.23 ± 2.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 8 mg/day +  usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 upper renal/4 mid‐renal/9 lower renal/4 pelvis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.45 ± 1.73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Presumed single center/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single radio‐opaque renal or upper ureteral stones ≤ 2 cm in largest diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months or until stone free</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic Siemens Lithostar; max 4000 shocks; 14–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 renal (5 upper calyx/3 mid‐calyx/12 lower calyx/15 pelvis)/28 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 ± 1.8 renal, 9.7 ± 2.6 ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (sodium diclofenac 50 mg oral or 75 mg IM PRN) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 renal (4 upper calyx/6 mid‐calyx/14 lower calyx/18 pelvis)/21 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 ± 2.3 renal, 8.6 ± 1.7 ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Presumed single center/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 to 10 mm single radio‐opaque upper ureteral stones (above iliac vessels)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotriptor Compact Sigma; max 4000 shocks; 14–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium, enteric‐coated tablets 75 mg PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008–2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal or ureteral stone 4–20 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Storz lithotriptor; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 renal/9 ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.22 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (ofluxacine 200 mg per 12 hours for 5 days; minimum 2 L fluid daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 renal/14 ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.88 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Solitary renal pelvic calculi who were successfully fragmented by ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium 75 mg PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazocin daily for up to 12 weeks + usual care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5–20 mm ureteric stone in any position</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (analgesic not further specified 1 week PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Males with solitary, radio‐opaque upper urinary tract stones, ≤ 20 mm in the max diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks after last SWL session</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 renal/12 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 ± 4.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (drink liberal fluids, analgesic not further specified PRN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 renal/10 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 ± 4.82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral stone 6–12 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Piezolith‐3000; 3000 shocks; 15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (drink 2 L fluid daily)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Singapore</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteric or renal stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin XL 10 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 renal/8 upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care only (not further described)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 renal/7 upper ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Males with ureteral stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 0.8 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (pain relieving therapy)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Presumed single center/Morocco</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral stones undergoing ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Storz MODULITH SLX‐F2; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 upper calyx/23 mid‐calyx/79 pelvis/54 lumbar ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 ± 2.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 25 mg TID; minimum 2 L water daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 upper calyx/19 mid‐calyx/75 pelvis/50 lumbar ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 ± 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≥ 4 mm ureteral stone with acute pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Compact Delta II, E‐3000, Sonolith Praktis; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg and diclofenac 100 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 renal/50 upper ureteral/47 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 renal/34 upper ureteral/39 lower ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≤ 10 mm upper and lower ureteral stone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sonolith Praktis; 2500–3000 shocks; 10–18 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg and pethidine 50 mg IV (once during SWL) + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 upper ureteral/24 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Education for hydration and exercise + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 upper ureteral/13 lower ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Males with ureteral stones &gt; 4 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Until stone clearance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dornier lithotripter, Stoltz SLX‐MX, Simens modularis variostar; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 proximal ureteral/3 mid‐ureteral/8 distal ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.61 ± 4.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 50 mg suppository PRN; 2 L water per day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 proximal ureteral/3 mid‐ureteral/8 distal ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.85 ± 3.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0023" title="KüpeliB , IrkilataL , GürocakS , TunçL , KiraçM , KaraoglanU , et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?Urology2004;64(6):1111-5. ">Küpeli 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2003–2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral stones within the distal 5 cm of the ureter 3–15 mm in size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Siemens Lithostar Plus; 2000–3500 shocks; 18.7 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium 100 mg/day for 15 days; oral hydration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants with urinary stone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin or silodosin + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 renal/24 ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (analgesic PRN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 renal/26 ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single ureteral stone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (hydration, antibiotics, acetaminophen PRN)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2003–2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Radiopaque or radiolucent ureteral lithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dornier Lithotripter S; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg; ketoprofene 50 mg BID for 7 days + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 ± 2.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 75 mg IM PRN; 1.5–2 L water daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 ± 1.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Solitary ureteric stone 5–15 mm diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Dornier SII; max 3000–4000 shocks; 12–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 upper ureteral/14 mid‐ureteral/26 lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (furosemide 20 mg every morning; diclofenac sodium 50 mg TID or a 75 mg ampoule PRN; oral fluids) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 upper ureteral/13 mid‐ureteral/21 lower ureteral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single radiopaque renal stone (5–20 mm) undergoing ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Siemens Lithostar‐Multiline; max 3500 shocks; 13.4–15.1 kV </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 renal pelvis/9 superior calyx/4 middle calyx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.12 ± 3.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (NSAIDs, antispasmodics or tramadol PRN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 renal pelvis/7 superior calyx/6 middle calyx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.06 ± 3.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011–2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages 18–70 years with symptomatic, unilateral and single proximal ureteral stones 6–20 mm in the longest axis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sonolith Praktis electroconductive lithotripter EDAP TMS S.A.; NR; NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proximal ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (aceclofenac 100 mg PRN; 1.5–2 L water daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single radio‐opaque renal stone (0.5–2.0 cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic shock wave generator Storz Medical Modulith SLK; max 4000 shocks; max 70 kV </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 pelvis/17 lower renal/5 mid‐renal/2 upper renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2 ± 3.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac sodium 50 mg BID for 1 day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 pelvis/13 lower renal/3 mid‐renal/1 upper renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 ± 2.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Inclusion criteria for ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin (dose NR) + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (not further defined)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ureteral stones &lt; 10 mm treated with ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (not further defined)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0033" title="ShaikhAA , PatujoYH , ShaikhAB , ShaikhNA , JalbaniMH . Comparison of efficacy with and without tamsulosin as medical adjuvant therapy after extracorporeal shockwave lithotripsy in renal stone. Rawal Medical Journal2018;43(3):471-4. ">Shaikh 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages &gt; 18 to &lt; 50 years, single radio‐opaque and size &lt; 20 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg  + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 ± 2.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 50 mg BID)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.61 ± 3.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009 to NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Apparent ESWL‐fragmentation of renal stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin (dose NR) + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 ± 4.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (not further defined)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1 ± 2.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages ≥ 18 years with symptomatic, unilateral, solitary lower ureteric calculus 4–12 mm in major axis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter HK–ESWL–VI; max 3000 shocks; 12–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (antibiotics and diclofenac PRN during the study period; 2500 mL fluid daily) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages 18–70 years with symptomatic, unilateral and solitary upper ureteral calculi 6–15 mm in major axis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter HK–ESWL–VI; max 3000 shocks; 12–15 kV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Max 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac PRN during the study period; 2500 mL fluid daily)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single center/Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>7–19 mm stone diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (diclofenac 100 mg suppositories daily; diclofenac 25 mg) orally</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin 2 mg + usual care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2012–2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants who underwent successful SWL (fragments &lt; 4 mm) for single renal stone ≤ 2 cm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (analgesic and anti‐inflammatory)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ages &gt; 18 years, radio‐opaque non‐lower pole renal stone (5–20 mm) and ESWL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Electromagnetic lithotripter Dornier Compact Delta Lithotriptor; 4000 shocks; 11–14 kV </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 superior calyx/13 mid‐calyx/14 pelvis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (celecoxib 200 mg BID PRN; 3 L liquid daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 superior calyx/16 mid‐calyx/15 pelvis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral stones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg + usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6 ± 2.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care (not further defined)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± 3.1</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>BID: twice daily; ESWL: extracorporeal shock wave lithotripsy; IM: intramuscular; IV: intravenous; max: maximum; n: number; NR: not reported; NSAID: non‐steroidal anti‐inflammatory drug; PRN: on demand; SD: standard deviation; SWL: shock wave lithotripsy; TID: three times daily. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013393-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included studies and imaging modality used to assess stone clearance</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomized (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analyzed (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial (n [%])</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up imaging modality</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0001" title="AgarwalMM , NajaV , SinghSK , MavuduruR , MeteUK , KumarS , et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteric stones: results of an open label randomized nonplacebo controlled study. Urology2009;74(5):989-92. ">Agarwal 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB</p> <p> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs, antispasmodics or tramadol PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0002" title="AhmedAF , ShalabyE , El-FekyM , KotbA , ElsotohiE , El-KholyM , et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis2016;97(3):266-72. ">Ahmed 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>326/279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (91.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB, ultrasound and CT<br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac potassium 50 mg BID for 2 days, additional doses PRN; drink plenty of fluids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 (92.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249 (91.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0003" title="AteşF , ErylıdırımB , ÖztürkMI , TuranT , GürbüzC , EkinciMO , et al. Does the use of doxazosin influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. Urological Research2012;40(5):537-42. AtesF , EryildirimB , IozturkM , TuranT , GurbuzC , EkinciMO , et al. Does the use of alpha blockers influence the success of SWL in the treatment of upper ureteral stones? A multicenter, prospective and randomized study. European Urology2011;10(7):515. ">Ateş 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazosin 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p> KUB<br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium PRN; drink fluid to provide urine output ≥ 2 L/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (NR)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 (87.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0004" title="BalochH , El KhalidS . Efficacy of Alfuzosin (alpha blocker) after extra corporeal shockwave lithotripsy for passage of renal calculi. European Urology2011;10(7):479. ">Baloch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard analgesia on demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0005" title="BhagatSK , ChackoNK , KekreNS , GopalakrishnanG , AntonisamyB , DevasiaA . Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?Journal of Urology2007;177(6):2185-8. ">Bhagat 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p> KUB<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proxyvon (dextropropoxyphene hydrochloride 65 mg and acetaminophen 400 mg ) daily PRN; minimum 2.5 L fluids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (96.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0006" title="CakırogluB , SinanogluO , UrazM . The effect of tamsulosin on pain and clearance according to ureteral stone location after shock wave lithotripsy. Current Therapeutic Research, Clinical and Experimental2013;74:33-5. ">Cakıroglu 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 75 mg IM on demand, pantoprazole 40 mg/day, after discharge drink 2 L water daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (NR)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0007" title="ChauH , ChanHC , LiTB , CheungMH , LamKM , SoHS . Prospective randomized controlled trial for patient with renal stone undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?BJU International2015;115(S1):9-10. ">Chau 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analgesic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0008" title="ChoHJ , ShinSC , SeoDY , MinDS , ChoJM , KangJY , et al. Efficacy of alfuzosin after shock wave lithotripsy for the treatment of ureteral calculi. Korean Journal of Urology2013;54(2):106-10. ">Cho 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (91.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loxoprofen sodium 68.1 mg PRN; 2 L fluids daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (95.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (93.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD013393-bbs2-0009" title="De NunzioC , BrassettiA , BellanginoM , LombardoR , PresicceF , VoglinoO , et al. Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: a randomized placebo controlled study. European Urology Supplements2016;15(3):e458. De NunzioC , BrassettiA , BellanginoM , TrucchiA , PettaS , PresicceF , et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology2016;30(7):817-21. ">De Nunzio 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Ultrasound and CT<br/> <br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 8 mg/day for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (90.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0010" title="Elkoushy MA . Adjuvant alpha adrenergic blockers: are they equally efficient for renal and upper ureteral calculi disintegrated by shock wave lithotripsy?African Journal of Urology2012;18(1):24-8. ElkoushyMA . Adjuvant alpha adrenergic blockers for renal and upper ureteral calculi disintegrated by shock wave lithotripsy. Journal of Endourology2010;24(S1):A103-4. ">Elkoushy 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sodium diclofenac 50 mg oral or 75 mg IM PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0011" title="EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following shock wave lithotripsy in ureteral calculi: an effective approach for the improvement of health-related quality of life. Urologia Internationalis2016;97(3):260-5. EryildirimB , SahinC , TuncerM , SabuncuK , TarhanF , SaricaK . Medical expulsive therapy following SWL in ureteral calculi: an effective approach for the improvement of health-related quality of life. European Urology Supplements2017;16(3):e66. ">Eryildirim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium, enteric‐coated tablets 75 mg PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (67.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0012" title="FalahatkarS , KhosropanahI , VajaryAD , BateniZH , KhosropanahD , AllahkhahA . Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi?Journal of Endourology2011;25(3):495-8. ">Falahatkar 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (93.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ofluxacine 200 mg per 12 hours for 5 days; minimum 2 L fluid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 (94.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD013393-bbs2-0013" title="GaafarSE , MotaweeO , MarzoukME , FodaMK , ZahranAM . Role of alpha-adrenergic blockers in enhancing clearance of stone fragments after ESWL of renal calculi. European Urology2011;10(7):479-80. ">Gaafar 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium 75 mg PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxazocin daily for up to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0014" title="HC , YuiL . Prospective randomized controlled trial for patients with ureteric stones undergoing extracorporeal shockwave lithotripsy (ESWL) using tamsulosin as adjuvant medical explusive therapy: are there any added benefits?International Journal of Urology2012;19(S1):172. ">H 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analgesic 1 week PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0015" title="HammoudKM , HindawyW , GalalM , SadekS . Does tamsulosin improve the results of SWL for upper urinary tract stones?Journal of Urology2014;191(4 Suppl 1):e204. ">Hammoud 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drink liberal fluids, analgesic PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0016" title="HanMC , JeongWS , ShimBS . Additive expulsion effect of tamsulosin after shock wave lithotripsy for upper ureteral stones. Korean Journal of Urology2006;47(8):813-7. ">Han 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p> KUB and IVP</p> <p> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drink 2 L fluid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0017" title="HongSK , TanYK , ChongYL . A pilot study on the use of alfuzosin as medical expulsive therapy after extracorporeal shockwave lithotripsy. Journal of Endourology2012;26(S1):A107. ">Hong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfuzosin XL 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0018" title="ItayaN , SugataA , HayashiK , HaraH , TamuboM , SisidoT , et al. Efficacy of an alpha1-blocker in expulsive therapy of ureteral stone after shock wave lithotripsy. Journal of Endourology2011;25(S1):A248. ">Itaya 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silodosin 0.8 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain relieving therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0019" title="JananeA , HamdounA , HajjiF , DakkakY , GhadouaneM , AmeurA , et al. Usefulness of adjunctive alpha1-adrenergic antagonists after single extracorporeal shock wave lithotripsy session in ureteral stone expulsion. Canadian Urological Association Journal2014;8(1-2):E8-E11. ">Janane 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB, ultrasound and CT<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 25 mg TID; minimum 2 L water daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0020" title="KangDI , ChoWY , KimTH , ChungJM , ParkJ , YoonJH , LeeSD . Effect of tamsulosin 0.2 mg on the short-term treatment of urinary stones: multicenter, prospective, randomized study. Korean Journal of Urology2009;50(6):586-90. ">Kang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg and diclofenac 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0021" title="KimTH , OhSY , MoonYT . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Korean Journal of Urology2008;49(12):1100-4. ">Kim 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg and pethidine 50 mg IV (once during SWL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB, IVP or CT<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Education for hydration and exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0022" title="KobayashiM , NayaY , KinoM , AwaY , NagataM , SuzukiH , et al. Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: efficacy in Japanese male patients with ureteral stone. International Journal of Urology2008;15(6):495-8. ">Kobayashi 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 50 mg suppository PRN; 2 L water per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0023" title="KüpeliB , IrkilataL , GürocakS , TunçL , KiraçM , KaraoglanU , et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?Urology2004;64(6):1111-5. ">Küpeli 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and CT<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium 100 mg/day for 15 days; oral hydration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0024" title="LanchonC , RonnaM , DescotesJL , RambeaudJJ , FiardG , ThuillierC , et al. Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: a randomized controlled trial. European Urology Supplements2017;16(3):e65. ">Lanchon 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin or silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analgesic PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0025" title="LiuY , ZhuangS , MaL . Low-dose tamsulosin improves clinical effect of single extracorporeal shock wave lithotripsy for ureteral calculi. Urology2009;74(4 Suppl 1):S136. ">Liu 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conservative therapy PRN, e.g. hydration, antibiotics, acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0026" title="MicaliS , GrandeM , SighinolfiMC , De StefaniS , BianchiG . Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urological Research2007;35(3):133-7. ">Micali 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg; ketoprofene 50 mg BID for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB, ultrasound and CT<br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 75 mg IM PRN; 1.5–2 L water daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0027" title="MohamedHI . The efficacy of tamsulosin therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: a prospective randomised, controlled study. Arab Journal of Urology2013;11(4):398-404. ">Mohamed 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>156/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Furosemide 20 mg every morning; diclofenac sodium 50 mg TID or a 75 mg ampoule PRN; oral fluids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0028" title="NajaV , AgarwalMM , MandalAK , SinghSK , MavuduruR , KumarS , et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology2008;72(5):1006-11. ">Naja 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (76.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSAIDs, antispasmodics or tramadol PRN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (90.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (83.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0029" title="ParkYH , LeeHE , ParkJY , LeeSB , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Korean Journal of Urology2013;54(8):527-30. ParkYH , ParkJY , AhnH , KimHH . A prospective randomized controlled trial of the efficacy of tamsulosin after extracorporeal shock wave lithotripsy for a single proximal ureteral stone. Journal of Endourology2013;27(S1):A263-4. ">Park 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (91.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aceclofenac 100 mg PRN; 1.5–2 L water daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (91.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (91.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0030" title="QadriSS , KhalidSE , MahmudSM . Effects and outcome of tamsulosin more than just stone clearance after extracorporeal shock wave lithotripsy for renal calculi. Journal of the Pakistan Medical Association2014;64(6):644-8. ">Qadri 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac sodium 50 mg BID for 1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0031" title="RakeshS , SubrataMK , RanjanDK , SupriyaB , RanjitDK . Is adjuvant therapy helpful for successful outcome in patients undergoing ESWL?Indian Journal of Urology2015;31(S1):S81. ">Rakesh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin (dose NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0032" title="SeungokY , JeongkiL , TaeYJ , YunBK . The effect of tamsulosin on expulsion of ureteral stones after extracorporeal shock wave lithotripsy. Journal of Endourology2009;23(Suppl 1):A169. ">Seungok 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0033" title="ShaikhAA , PatujoYH , ShaikhAB , ShaikhNA , JalbaniMH . Comparison of efficacy with and without tamsulosin as medical adjuvant therapy after extracorporeal shockwave lithotripsy in renal stone. Rawal Medical Journal2018;43(3):471-4. ">Shaikh 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 50 mg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0034" title="SighinolfiMC , MicaliS , MofferdinA , PiniG , IsgroG , De StefaniS , et al. Efficacy of tamsulosin treatment after extracorporeal shock wave lithotripsy of stones located in the kidney: a prospective and randomized study on 129 patients. Journal of Endourology2010;24(Suppl 1):A106. ">Sighinolfi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin (dose NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No alpha‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0035" title="SinghSK , PawarDS , GriwanMS . Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly2011;3(1):62-8. ">Singh 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound      <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics and diclofenac PRN during the study period; 2500 mL fluid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (98.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (99.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0036" title="SinghSK , PawarDS , GriwanMS , IndoraJM , SharmaS . Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology Journal2011;8(1):14-20. ">Singh 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac PRN during the study period; 2500 mL fluid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (NR)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (97.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD013393-bbs2-0037" title="TajariH , PedramP , KeshtkarA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosin in alphaadrenergic blockers after ESWL (a double blind clinical trial). Urology2009;74(4):S340-1. TajariH , PedramPM , KeshtkarAA , Ghazi MoghadamB , AmidiA . The comparison between efficacy of tamsulosin and terazosinin alpha-adrenergic blockers after ESWL (a double blind clinical trial). Journal of Endourology2009;23(11):A33-4. ">Tajari 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR<br/> <br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 100 mg suppositories daily; diclofenac 25 mg orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terazosin 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0038" title="TelebM , DawodT , SalemE , RagabA , ShabanaW , FawziA , et al. The efficacy of tamsulosin in stone clearance after shock wave lithotripsy for renal calculi. European Urology Supplements2015;14(2):e99. ">Teleb 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analgesic and anti‐inflammatory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0039" title="VicentiniF , MazzucchiE , BritoA , NetoEC , DanilovicA , EbaidG , et al. Adjuvant use of tamsulosin and nifedipine after extracorporeal shock waves lithotripsy in patients with kidney stones – a prospective, double-blind and randomized study. Journal of Urology2011;184(4 Suppl 1):e898. VicentiniFC , MazzucchiE , BritoAH , Chedid NetoEA , DanilovicA , SrougiM . Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology2011;78(5):1016-21. ">Vicentini 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (84.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>KUB and ultrasound<br/> <br/> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Celecoxib 200 mg BID PRN; 3 L liquid daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (82.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (83.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD013393-bbs2-0040" title="WangHJ , LiuK , JiZG , LiHZ . Application of α1-adrenergic antagonist with extracorporeal shock wave lithotripsy for lower ureteral stone. Acta Academiae Medicinae Sinicae2008;30(4):506-8. ">Wang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (100)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>BID: twice daily; CT: computer tomography; IM: intramuscular; IV: intravenous; IVP: intravenous pyelography; KUB: kidney, ureter, bladder radiograph; n: number; NR: not reported; NSAID: non‐steroidal anti‐inflammatory drug; PRN: on demand; SWL: shock wave lithotripsy; TID: three times daily. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included studies and imaging modality used to assess stone clearance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/full#CD013393-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013393-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Stone clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.09, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Auxiliary treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.46, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Stone clearance time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.74 [‐5.25, ‐2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013393-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: stone location subgroup (renal and proximal ureter versus distal ureter)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Stone clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.11, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Renal and upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.06, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.13, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Auxiliary treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Renal and upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Lower ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.26, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.46, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Renal and upper ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.44, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Lower ureteral </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.26, 3.83]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: stone location subgroup (renal and proximal ureter versus distal ureter)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013393-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: stone location subgroup (renal versus ureter; post hoc)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Stone clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.11, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.03, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Ureter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.14, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Auxiliary treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.25, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Ureteral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.44, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.46, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Renal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.44, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Ureteral </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.26, 3.83]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: stone location subgroup (renal versus ureter; post hoc)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013393-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: stone size subgroup</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Stone clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.00, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 &lt; 10 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.96, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 ≥ 10 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.02, 1.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: stone size subgroup</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013393-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Stone clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.09, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.09, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.87, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.46, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.4 Alfuzosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.89, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.5 Naftopidil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [0.50, 22.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.6 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.00, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Auxiliary treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.46, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Doxazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.06, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.08, 41.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.46, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.45, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Silodosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.08, 41.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013393-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Alpha‐blockers and usual care versus usual care: risk of bias (sensitivity analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Stone clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.86, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Auxiliary treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.03, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.32, 3.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Alpha‐blockers and usual care versus usual care: risk of bias (sensitivity analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013393-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: single SWL session (sensitivity analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Stone clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.04, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Auxiliary treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.54, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.45, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Alpha‐blocker and usual care versus usual care: single SWL session (sensitivity analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013393.pub2/references#CD013393-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013393.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013393-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013393-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013393-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013393-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013393-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013393-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013393-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013393-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013393-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013393\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013393\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013393\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013393\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013393\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013393.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013393.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013393.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013393.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013393.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720288691"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013393.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720288695"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013393.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfd81ff209377',t:'MTc0MDcyMDI4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 